Lifezone Metals Completes Acquisition of Hydromet Lab and Engineering Firm, Simulus Group

Bringing Simulus in-house expands capabilities for Lifezone Metals’ growth strategy

New York (United States), Perth (Australia), July 27, 2023 (GLOBE NEWSWIRE) — Lifezone Metals Limited (“Lifezone Metals” or the “Company”) (NYSE: LZM), a modern metals company creating value across the battery metals supply chain from resource to metals production and recycling, is pleased to announce the acquisition of The Simulus Group Pty Limited (“Simulus” or “Simulus Group”) has concluded.

Lifezone Metals has a long-standing commercial relationship with the Simulus Group – a Perth-based hydrometallurgy (“hydromet”) laboratory and engineering company – that was Lifezone Metals’ metallurgical laboratory of choice for years, having supported a number of studies and test work on our Kabanga and Sedibelo projects. We consider the acquisition to be the logical next step, allowing us to shorten testing times, avoiding regular delays when using third party laboratories, and controlling external costs.

Founder and Chair of Lifezone Metals, Keith Liddell, said: “We believe that Simulus Group is one of the best hydrometallurgical laboratories in the world and acquired the company to incorporate their hydromet technology, lab capabilities, and technical excellence into our business as we grow to become a global metals company. At a time when the world is racing to tackle the climate crisis, this technology will provide a responsible solution to delivering the battery metals needed to support decarbonisation of the global economy.”  

Over the coming months, we will be planning for and integrating the Simulus facilities and teams into the Operating division of Lifezone Metals under Chief Operating Officer, Gerick Mouton. Once integrated, the aim will be to streamline the test work and further development of hydromet, bringing the technology solution closer to commercialisation – and in turn reducing the emissions produced as a result of processing and recycling of battery metals.  

Lifezone Metals has a solid pipeline of projects, including the Kabanga nickel project, autocatalyst recycling and further expansion of the portfolio as it grows, which will be supported by the lab and engineering capabilities of Simulus and may in time require an expansion of the current facilities.

The acquisition of Simulus is a key piece of Lifezone Metals’ long-term strategy and is an enabler to our ultimate mission: Developing a supply chain solution for clean metals.

If you would like to sign up for Lifezone Metals news alerts, please register here.

About Lifezone Metals

Lifezone Metals (NYSE: LZM) is a modern metals company creating value across the battery metals supply chain from resource to metals production and recycling. Our mission is to provide commercial access to proprietary technology and cleaner metals production through a scalable platform underpinned by our tailored hydromet technology. This technology has the potential to be a cleaner and lower cost alternative to smelting, allowing us to responsibly and cost-effectively provide cleaner metals.

By pairing the Kabanga Project in Tanzania, which we believe is one of the largest and highest-grade undeveloped nickel sulphide deposits in the world, with our proprietary Hydromet Technology, we will work to unlock the value of a key new source of supply to global battery metals markets. We have a long-standing partnership with BHP on the Kabanga Project, with BHP having invested USD100 million, as we work to empower Tanzania to achieve full value creation in-country and become the next premier source of nickel.

 www.lifezonemetals.com 

Forward-Looking Statements

Certain statements made herein are not historical facts but may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the business combination between GoGreen Investments Corporation (“GoGreen”) and Lifezone Holdings Limited (“LHL”) that formed Lifezone Metals, the estimated or anticipated future results of Lifezone Metals, future opportunities for Lifezone Metals, including the efficacy of Lifezone Metals’ hydromet technology (“Hydromet Technology”) and the development of, and processing of mineral resources at, the Kabanga Project, and other statements that are not historical facts.

These statements are based on the current expectations of Lifezone Metals’ management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Lifezone Metals. These statements are subject to a number of risks and uncertainties regarding Lifezone Metals’ business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to the economic and operational disruptions and other effects of the COVID-19 pandemic; the outcome of any legal proceedings that may be instituted against the Lifezone Metals in connection with the business combination; failure to realize the anticipated benefits of the business combination, including difficulty in integrating the businesses of LHL and GoGreen; the risks related to the rollout of Lifezone Metals’ business, the efficacy of the Hydromet Technology, and the timing of expected business milestones; Lifezone Metals’ development of, and processing of mineral resources at, the Kabanga Project; the effects of competition on Lifezone Metals’ business; the ability of Lifezone Metals to execute its growth strategy, manage growth profitably and retain its key employees; the ability of Lifezone Metals to maintain the listing of its securities on a U.S. national securities exchange; costs related to the business combination; our ability to successfully integrate Simulus into our business; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission. Additional information pertaining to the acquisition of the Simulus Group, including the risks related thereto, is set forth in the section of Lifezone Metals’ Registration Statement on Form F-4 (File No. 333-271300) filed with the SEC on April 17, 2023 titled “Risk Factors — There can be no assurance that we will complete the Simulus Acquisition. Failure to complete the Simulus Acquisition, or to successfully integrate SGPL into our business upon completion of the Simulus Acquisition, may adversely affect our business and operations. If the Simulus Acquisition is completed, in addition to the cash consideration, we will be required to issue Lifezone Metals’ Ordinary Shares to the shareholders of SGPL, which will result in dilution to Lifezone Metals’ existing shareholders,” which is incorporated herein by reference. The foregoing list of risk factors is not exhaustive. There may be additional risks that Lifezone Metals presently does not know or that Lifezone Metals currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Lifezone Metals’ expectations, plans or forecasts of future events and views as of the date of this communication. Lifezone Metals anticipates that subsequent events and developments will cause Lifezone Metals’ assessments to change. However, while Lifezone Metals may elect to update these forward-looking statements in the future, Lifezone Metals specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Lifezone Metals’ assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results in such forward-looking statements will be achieved.  You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Certain statements made herein include references to “clean” or “green” metals, methods of production of such metals, energy or the future in general. Such references relate to environmental benefits such as lower green-house gas (“GHG”) emissions and energy consumption involved in the production of metals using the Hydromet Technology relative to the use of traditional methods of production and the use of metals such as nickel in the batteries used in electric vehicles. While studies by third parties (commissioned by Lifezone Metals) have shown that the Hydromet Technology, under certain conditions, results in lower GHG emissions and lower consumption of electricity compared to smelting with respect to refining platinum group metals, no active refinery currently licenses Lifezone Metals’ Hydromet Technology. Accordingly, Lifezone Metals’ Hydromet Technology and the resultant metals may not achieve the environmental benefits to the extent Lifezone Metals expects or at all. Any overstatement of the environmental benefits in this regard may have adverse implications for Lifezone Metals and its stakeholders.

Attachment



Natasha Liddell
Chief Sustainability & Communications Officer, Lifezone Metals
[email protected]

Ingo Hofmaier
Chief Financial Officer, Lifezone Metals
[email protected]

ICR, Inc.
Investor Relations, ICR, Inc.
646-200-8879
[email protected]

Bronwyn Wallace
US Media Enquiries, H+K Strategies
+1 (713) 724 3627
[email protected]

Ermenegildo Zegna Group’s Robust Growth Continues in the First Half of 2023

Ermenegildo Zegna Group’s Robust Growth Continues in the First Half of 2023

  • First half 2023 Revenues1 reach €903 million, up 23.9% year-over-year.
  • Organic growth2 was 21.5% in the first half of 2023, with double-digit organic growth for both the Zegna and Thom Browne segments.
  • Acceleration in the second quarter with year-over-year growth of 35.1% and organic growth of 24.5%, led by solid double-digit organic performance in all major geographies and notable strength in the US.
  • Direct-to-consumer year-over-year growth (36.3% for the first half and 48.1% for the second quarter of 2023) continues to be dynamic across all regions for Zegna and Thom Browne, with both posting organic growth of around 30% for the first half of 2023 and of 36.2% and 33.7% in the second quarter of 2023, respectively.
  • Robust first half supports the Group’s FY 2023 and mid-term outlook.

MILAN–(BUSINESS WIRE)–
Ermenegildo Zegna N.V. (NYSE:ZGN) (“Zegna Group,” the “Group,” “Zegna,” or the “Company”), owner of the ZEGNA and Thom Browne brands and exclusive licensee for the TOM FORD fashion business (“TOM FORD FASHION”), today announced preliminary unaudited revenues of €903 million for the first half of 2023, an increase of 23.9% year-over-year. Revenues at constant currency3 were up 24.7%, and organic growth was 21.5%. Revenues for the first half of 2023 reflect the consolidation of Tom Ford International LLC starting from April 29, 2023, as well as the consolidation of Pelletteria Tizeta S.r.l., (which was previously accounted for using the equity method), as of the same date.

Unaudited revenues for the second quarter of 2023 were €475 million, an increase of 35.1% year-over-year. For the same period, revenues at constant currency were up 37.4%, and organic growth was 24.5%, representing an acceleration compared to the 18.9% organic growth recorded in the first quarter of 2023.

Ermenegildo “Gildo” Zegna, Chairman and CEO of the Zegna Group, said: “The second quarter of 2023 has built on the Group’s excellent performance since the beginning of the year. Our brands continue to resonate strongly with customers worldwide, with a positive rebound in China in the first half of the year, our persistent strength in EMEA, and our outstanding performance in the U.S. market.”

“I am particularly pleased that we are gaining market share, and I am confident about the strong opportunities ahead as the menswear segment grows globally with both existing and new audiences. Our ZEGNA, Thom Browne, and TOM FORD FASHION brands all offer distinctive styles that cater to a wide range of shoppers and occasions, allowing us to be leaders across the luxury market. The strong execution of the One Brand strategy has made ZEGNA a global favorite, with successful collections which include staple Luxury Leisurewear items and our signature Triple Stitch™ sneaker. At Thom Browne, the work being done to strengthen womenswear continues to show great progress and the category is now outpacing the growth of menswear. Meanwhile, we have started our journey to make TOM FORD FASHION among the top ten luxury fashion names in the world. The Group’s financial progress underpins our confidence that we are comfortably on track to meet our previously announced 2025 financial ambitions.”

“I would also like to welcome Lelio Gavazza to the Zegna Group as Chief Executive Officer of TOM FORD FASHION. As we continue the integration of TOM FORD FASHION into the Group, I look forward to working with Lelio once he starts his new role in September. In partnership with the Estée Lauder Companies, we will build upon Tom’s legacy to grow this iconic, one-of-a-kind luxury brand globally.”

“Finally, our family’s commitment to social responsibility over 113 years was once again highlighted last week when we celebrated the 10th anniversary of the Ermenegildo Zegna Founder’s Scholarship, which enables Italian graduates to pursue their postgraduate studies abroad and return home. This program is a particular point of pride for me as it brings back Italian talents to contribute to the future of Italy.”

________________________________

1 Throughout this press release, revenues for the first half of 2023 and the second quarter of 2023 are preliminary and unaudited.

2 Organic growth is a non-IFRS financial measure. See the Non-IFRS Financial Measures section starting on page 12 of this press release for the definition of such non-IFRS financial measure and a reconciliation to the most directly comparable IFRS measure.

3 Revenue growth at constant currency is a non-IFRS financial measure. See the Non-IFRS Financial Measures section starting on page 12 of this press release for the definition of such non-IFRS financial measure.

Highlights from the Second Quarter of 2023 and Recent Events

  • ZEGNA: Oasi di Lino, New Store Openings and Agreement with GBB

    • On June 19, during Milan men’s fashion week, ZEGNA brought Oasi Zegna to Piazza San Fedele in the heart of Milan. The brand’s collection showcased and was inspired by L’Oasi di Lino, a fabric made in Italy from flax plants grown in Normandy, France. Zegna commits to certifying Oasi Lino fibers as 100% traceable by 2024.

    • In the first half of the year, ZEGNA opened seven net new direct-to-consumer stores, bringing the total to 246. Store productivity also increased meaningfully over that period, driven by several factors including higher traffic, an increase in the number of transactions and in the average ticket, and store right-sizing.

    • On July 26, 2023, Zegna granted Give Back Beauty International SA exclusivity for the manufacture and sale of “Zegna” branded fragrances and cosmetics.

  • Thom Browne: Paris Couture Debut and New Store Openings

    • On July 3, Thom Browne presented a unique, highly anticipated Haute Couture collection in Paris, celebrating the brand’s 20th anniversary. The collection, which reflected the brand’s vision and Thom’s singular style, has received praise from critics, the media, celebrities and couture clients.

    • In the first half of the year, Thom Browne opened three net new direct-to-consumer stores, bringing the total to 66, up from 53 a year ago and 63 as of December 31, 2022. The three new stores in the APAC region – two in China and one in Japan – highlight the importance of the region to the brand and Thom Browne’s continued success and desirability.

    • As of July 1, Thom Browne began directly operating its Korean business and its network of 17 stores. The business is now wholly owned through Thom Browne Korea, a newly formed and wholly owned company, and will be operated in the region with external support from Samsung, previously its franchise partner.

  • TOM FORD FASHION: Acquisition Completed, License Begins and New CEO Appointed

    • On April 28, Zegna Group completed the acquisition of Tom Ford International LLC, the company that owns and operates TOM FORD FASHION. Upon closing, Zegna became a long-term licensee of The Estée Lauder Companies, the sole owner of TOM FORD brand, trademarks and other intellectual property rights, for all TOM FORD men’s and women’s fashion as well as accessories and underwear, fine jewelry, childrenswear, textile, and home design products.

    • On July 18, the appointment of Lelio Gavazza as the new CEO of TOM FORD FASHION was announced and he will be starting his role on September 18, 2023.

    • The addition of TOM FORD FASHION brings 51 direct-to-consumer and 70 monobrand wholesale locations to the Group’s network across the U.S., Europe, and APAC.

    • Peter Hawkings’ debut Womenswear fashion collection for Spring/Summer 2024 will take place in Milan during Fashion Week in September 2023.

  • Our Road to Sustainability: SBTi Targets Approval and Animal Welfare Policy

    • In August 2022, Zegna Group submitted its greenhouse gas emissions reduction targets to the Science-Based Targets initiative (SBTi), which approved the targets in May 2023. The Group is targeting net-zero greenhouse gas emissions (GHG) across its value chain by 2050 from a 2021 base year. In the near term, the Group has committed to reducing absolute scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, employee commuting, and investments by 50.4% by 2032.

    • On May 17, Zegna Group adopted its new animal welfare policy as part of its commitment to creating the best products from the highest-quality materials while ensuring the well-being and longevity of the natural environment and its inhabitants.

  • Made in Italy Luxury Textile Laboratory Platform: Acquisition of Minority Stake in Luigi Fedeli e Figlio

    • On June 6, Zegna Group and Prada Group announced the acquisition of 30% of Luigi Fedeli e Figlio, the world-renowned maker of fine Italian knitwear and yarns, with each group acquiring 15% of the company. The historic Italian company’s focus on quality and sustainability aligns perfectly with Zegna Group’s values and commitment to preserving and enhancing the craftsmanship of Made in Italy. This transaction is subject to customary closing conditions, including antitrust approvals.

Review of Revenues for the First Half 2023 and the Second Quarter 2023

In the second quarter of 2023, Zegna Group generated revenues of €475 million, an increase of 35.1% year-over-year. At constant currency, revenues grew 37.4%. Organic growth for the period was 24.5%.

Revenues by Segment

Zegna Segment: For the second quarter of 2023, revenues for the Zegna segment amounted to €332 million, growing by 23.4% year-over-year and 25.2% at constant currency. Organic growth was 28.2%. This brought revenues for the first half of the year to €652 million, up 17.9% from the first half of last year, and up 18.4% at constant currency. Organic growth for the first half of 2023 was 23.8%. The segment’s growth was driven by the very strong performance of Zegna-branded products in the quarter, particularly in direct-to-consumer, as well as a positive contribution from the Textile product line.

Thom Browne Segment: For the second quarter of 2023, revenues for the Thom Browne segment amounted to €95 million, growing by 8.1% year-over-year and with constant currency and organic growth of 10.8%. This brought Thom Browne segment revenues for the first half of the year to €208 million, up 11.9% from the first half of last year, and 13.6% constant currency and organic growth.

The growth of the Thom Browne segment in the second quarter of 2023 was driven by robust direct-to-consumer performance, which offset the slight decline in wholesale. On top of comparable stores growth, direct-to-consumer performance was also supported by the expansion of the brand’s store network, which added 13 net new stores since June 30, 2022.

Tom Ford Fashion Segment: Effective April 29, 2023, concurrently with the consolidation of Tom Ford International LLC in the Group’s financial statements, Tom Ford Fashion represents as a new operating and reporting segment of the Group. The Tom Ford Fashion segment includes all activities related to TOM FORD FASHION, from collection creation and development to merchandising, through to production, as well as retail and wholesale distribution. From April 29, 2023 to June 30, 2023, the segment reported revenues of €64 million.

Revenues by Product Line

Zegna-branded Products: Revenues for Zegna-branded products were at €269 million for the second quarter, up 33.9% year-over-year, with constant currency and organic growth of 37%. This brought first-half revenues for Zegna-branded products to €541 million, up 27.3% year-over-year, and with constant currency and organic growth of 28.4%.

The Made-to-Measure business continued to perform well, and together with sneakers and luxury leisurewear, have all shown consistent growth.

Thom Browne: Revenues for Thom Browne were at €94 million for the quarter, up 8.2% year-over-year, and with 11% constant currency and organic growth. This brought first half revenues for Thom Browne to €207 million, up 11.8% year-over-year, and 13.4% constant currency and organic growth.

The growth in Thom Browne revenues came from all product categories, with womenswear outperforming men’s and kid’s products also being a dynamic performer.

Textile: Textile revenues were flat at €39 million during the second quarter of 2023 compared to the prior year. This brought first half revenues to €73 million, up 6% year-over-year, 5.2% in constant currency. Organic growth for the first half was 5.3%.

Third-Party Brands: The performance in the second quarter of the Third-Party Brands product line reflects the end of the Tom Ford International distribution license. Revenues for the second quarter of 2023 were €6.6 million, down 71.4% year-over-year, -71.8% in constant currency, and -30.7% organic growth impacted by Tom Ford Products4, which starting from April 29, 2023, are reported as intercompany revenues, as a result of the acquisition of Tom Ford International LLC on April 28, 2023.

Revenues by Channel

The direct-to-consumer channel’s momentum was robust across both Zegna and Thom Browne, which reported in the second quarter of 2023, year-over-year growth of 32.7% and 25.3% respectively, and 36.2% and 33.7% year-over-year constant currency and organic growth, respectively. The strong global direct-to-consumer performance of Zegna branded products was driven by double-digit growth across all regions, and it was met by a remarkable improvement in retail productivity at the brands’ boutiques. Thom Browne benefitted from the expansion of its store network, as well as double-digit comparable store growth.

In the second quarter of 2023, Zegna’s branded products wholesale channel showed robust growth of 42.8% year-over-year and 43.0% constant currency and organic growth. Meanwhile, the Thom Browne segment wholesale activity was down 1.7% year-over-year for the quarter and with constant currency and organic growth down 1.5%, including the effects of lower deliveries during the quarter to the South Korean market, which, as previously announced, is directly operated as of July 1, 2023.

Revenues by Geography

The Group saw robust global growth across all regions during the second quarter of 2023, driven by all geographies.

Early signs of strong activity from Chinese consumers drove growth in the Greater China Region. Revenues from the region were exceptionally strong at €142 million, up 35.3% year-over-year for the quarter, or 42.0% at constant currency and 40.0% organic growth. The growth is especially strong in comparison to last year, which was adversely impacted by Covid-19-related restrictions. Sales in Hong Kong and Macau were particularly strong thanks to the healthy recovery in direct-to-consumer activity. The resumption of Chinese tourism, particularly to other Asian countries, is starting to show results, with strong year-over-year reported growth in Southeast Asia and 30.1% year-over-year reported growth (36.8% constant currency and 23.9% organic growth) in Japan.

Group revenues from the EMEA region for the second quarter were at €173 million, up 36.8% year-over-year, 37.9% in constant currency. Organic growth for the quarter was at 24.5%. Both the UAE and Europe performed exceptionally well, especially in Zegna direct-to-consumer, benefitting from both domestic and tourist customers. Growth in the region was underpinned by the strong performance in the UAE, where revenues grew by 49.4% year-over-year, 53.1% at constant currency and 50.8% organic growth. EMEA revenues for the first half of the year were at €323 million, up 23.8% year-over-year, 24.2% at constant currency, and 21.4% organic growth.

In the U.S., revenues were at €99 million for the quarter, up 46.5% year-over-year, and 45.3% in constant currency. Organic growth for the quarter was at 13.9%. This brought first-half revenues in the U.S. to €157 million, up 26.1% year-over-year, 22.9% in constant currency, and 12.5% organic growth. In the first half, the U.S. benefited from the contribution of the Tom Ford Fashion segment’s 11 directly operated stores, as well as solid double-digit performance in the Zegna and Thom Browne direct-to-consumer channels.

In Latin America, the Group’s revenues reached €9 million for the quarter, up 30.7% year-over-year, and with 23.9% constant currency and organic growth, driven by revenues from Zegna’s direct-to-consumer business in Mexico.

________________________________

4 As previously disclosed, the licensing agreement for the production and worldwide distribution of luxury men’s ready-to-wear and made-to-measure clothing, footwear, and accessories under the TOM FORD brand expired with the deliveries of the Fall/Winter 2022 collection, and a supply agreement to act as the exclusive supplier for certain TOM FORD menswear products commenced starting with the Spring/Summer 2023 collection.

Outlook

On May 17, 2022, at its first Capital Markets Day, the Group announced its financial goals for the medium term, which management defines as the end of fiscal year 2025. Within this time frame, the Group is aiming for annual revenues to exceed €2 billion and for Adjusted EBIT Margin to reach at least 15%, excluding the Tom Ford Fashion segment. The Group’s 1H 2023 revenues show that the Group is on this trajectory, and the forthcoming first half 2023 and full-year 2023 results should comfortably confirm this. The Group’s medium-term targets assume no further future escalation of the war in Ukraine, no significant macroeconomic or financial markets deterioration, no further disruption linked to the COVID-19 pandemic in the GCR or elsewhere, and no other unforeseen events.

***

Next Scheduled Announcement

The next scheduled announcement will be on September 13, 2023, in connection with the release of the Group’s semi-annual condensed consolidated financial statements at and for the six months ended June 30, 2023. To receive email alerts of the timing of future financial news releases, as well as future announcements, please register at https://ir.zegnagroup.com.

***

About Ermenegildo Zegna Group

Founded in 1910 in Trivero, Italy, the Ermenegildo Zegna Group (NYSE: ZGN) is a leading global luxury group. The Group is the owner of the world-renowned ZEGNA and Thom Browne brands, and operates TOM FORD FASHION through an exclusive long-term license agreement with The Estée Lauder Companies Inc. The Group also manufactures and distributes the highest quality fabrics and textiles through its Luxury Textile Laboratory Platform. At the Group’s core is a uniquely vertically integrated supply chain that brings together the best of Italian fine craftsmanship. Responsibility towards people, community and the natural world has been at the heart of the Ermenegildo Zegna Group’s belief since its founding. At the end of 2022, Ermenegildo Zegna Group had more than 6,000 employees and for the year ended December 31, 2022 had revenues of approximately €1.5 billion.

***

***

Forward Looking Statements

This communication, including the section “Outlook”, contains forward-looking statements that are based on beliefs and assumptions and on information currently available to the Company. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this communication, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, risks and uncertainties are described in the Company’s filings with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company and its directors, officers or employees or any other person that the Company will achieve its objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent the views of Zegna as of the date of this communication. Subsequent events and developments may cause that view to change. However, while Zegna may elect to update these forward-looking statements at some point in the future, the Company disclaims any obligation to update or revise publicly forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing the views of the Company as of any date subsequent to the date of this communication.

***

Second Quarter 2023 and First Half 2023 – Preliminary Unaudited Group Revenues

Group Revenues by Segment (Preliminary and Unaudited)

 

 

 

 

 

H1 2023 vs H1 2022

 

 

 

 

 

Q2 2023 vs Q2 2022

(€ thousands, except percentages)

H1 2023

 

H1 2022

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

Q2 2023

 

Q2 2022

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

 

 

 

 

 

 

 

 

 

Revenues

903,059

 

728,993

 

23.9%

 

24.7%

 

21.5%

 

474,747

 

351,414

 

35.1 %

 

37.4 %

 

24.5 %

Zegna segment

651,755

 

552,966

 

17.9%

 

18.4%

 

23.8%

 

332,431

 

269,443

 

23.4 %

 

25.2 %

 

28.2 %

Thom Browne segment

207,959

 

185,769

 

11.9%

 

13.6%

 

13.6%

 

94,708

 

87,641

 

8.1 %

 

10.8 %

 

10.8 %

Tom Ford Fashion segment

64,027

 

 

n.m.

 

n.m.

 

n.m.

 

64,027

 

 

n.m.

 

n.m.

 

n.m.

Eliminations

(20,682)

 

(9,742)

 

n.m.

 

n.m.

 

n.m.

 

(16,419)

 

(5,670)

 

n.m.

 

n.m.

 

n.m.

___________________________________

(*) Throughout this section “n.m.” means not meaningful

The tables below show a reconciliation of revenue growth for the six months ended June 30, 2023 and for the three months ended June 30 and March 31, 2023 to organic growth for the same periods by segment and at the Group level.

 

H1 2023 vs H1 2022

 

Revenues Growth

 

Foreign exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

Group

23.9 %

 

(0.8) %

 

8.8 %

 

(5.6) %

 

21.5 %

Zegna segment

17.9 %

 

(0.5) %

 

1.4 %

 

(6.8) %

 

23.8 %

Thom Browne segment

11.9 %

 

(1.7) %

 

— %

 

0%.0

 

13.6 %

Tom Ford Fashion segment

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

 

Q2 2023 vs Q2 2022

 

Revenues Growth

 

Foreign exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

Group

35.1 %

 

(2.3) %

 

18.4 %

 

(5.5) %

 

24.5 %

Zegna segment

23.4 %

 

(1.8) %

 

2.7 %

 

(5.7) %

 

28.2 %

Thom Browne segment

8.1 %

 

(2.7) %

 

— %

 

— %

 

10.8 %

Tom Ford Fashion segment

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

 

Q1 2023 vs Q1 2022

 

Revenues Growth

 

Foreign exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

Group

13.4 %

 

0.3 %

 

— %

 

(5.8) %

 

18.9 %

Zegna segment

12.6 %

 

0.7 %

 

— %

 

(7.8) %

 

19.7 %

Thom Browne segment

15.4 %

 

(0.7) %

 

— %

 

— %

 

16.1 %

Tom Ford Fashion segment

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

Group Revenues by Product Line (Preliminary and Unaudited)

 

 

 

 

 

H1 2023 vs H1 2022

 

 

 

 

 

Q2 2023 vs Q2 2022

(€ thousands, except percentages)

H1 2023

 

H1 2022

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

Q2 2023

 

Q2 2022

 

Reported

Revenues

 

Constant

Currency

 

Organic

growth

 

 

 

 

 

 

 

 

 

 

Total revenues

903,059

 

728,993

 

23.9%

 

24.7%

 

21.5%

 

474,747

 

351,414

 

35.1%

 

37.4%

 

24.5%

Zegna branded products

541,319

 

425,252

 

27.3%

 

28.4%

 

28.4%

 

269,430

 

201,273

 

33.9%

 

37.0%

 

37.0%

Thom Browne

206,951

 

185,166

 

11.8%

 

13.4%

 

13.4%

 

94,399

 

87,229

 

8.2%

 

11.0%

 

11.0%

Tom Ford Fashion

64,015

 

 

n.m.

 

n.m.

 

n.m.

 

64,015

 

 

n.m.

 

n.m.

 

n.m.

Textile

73,072

 

68,968

 

6.0%

 

5.2%

 

5.3%

 

39,254

 

38,724

 

1.4%

 

0.3%

 

0.6%

Third Party Brands

15,477

 

47,341

 

(67.3%)

 

(68.1%)

 

(4.4%)

 

6,567

 

22,939

 

(71.4%)

 

(71.8%)

 

(30.7%)

Other

2,225

 

2,266

 

(1.8%)

 

(2.3%)

 

(2.1%)

 

1,082

 

1,249

 

(13.4%)

 

(13.1%)

 

(12.7%)

________________________________________

Zegna branded products include apparel, bags, shoes and small and large leather goods, as well as licensed goods and royalties.

The tables below show a reconciliation of revenue growth for the six months ended June 30, 2023 and for the three months ended June 30, 2023 to organic growth for the same periods by product line and at the Group level.

 

H1 2023 vs H1 2022

 

Revenues Growth

 

Foreign exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

Group

23.9 %

 

(0.8) %

 

8.8 %

 

(5.6) %

 

21.5 %

Zegna branded products

27.3 %

 

(1.1) %

 

— %

 

— %

 

28.4 %

Thom Browne

11.8 %

 

(1.6) %

 

— %

 

— %

 

13.4 %

Tom Ford Fashion

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

Textile

6.0 %

 

0.8 %

 

(0.1) %

 

— %

 

5.3 %

Third Party Brands

(67.3) %

 

0.8 %

 

(0.1) %

 

(63.6) %

 

(4.4) %

Other

(1.8) %

 

0.5 %

 

(0.2) %

 

— %

 

(2.1) %

 

Q2 2023 vs Q2 2022

 

Revenues Growth

 

Foreign exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

Group

35.1 %

 

(2.3) %

 

18.4 %

 

(5.5) %

 

24.5 %

Zegna branded products

33.9 %

 

(3.1) %

 

— %

 

— %

 

37.0 %

Thom Browne

8.2 %

 

(2.8) %

 

— %

 

— %

 

11.0 %

Tom Ford Fashion

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

Textile

1.4 %

 

1.1 %

 

(0.3) %

 

— %

 

0.6 %

Third Party Brands

(71.4) %

 

0.4 %

 

— %

 

(41.1) %

 

(30.7) %

Other

(13.4) %

 

(0.3) %

 

(0.4) %

 

— %

 

(12.7) %

________________________________________

Zegna branded products include apparel, bags, shoes and small and large leather goods, as well as licensed goods and royalties.

Group Revenues by Sales Channel (Preliminary and Unaudited)

 

 

 

 

 

 

 

 

 

H1 2023 vs H1 2022

 

 

 

 

 

 

 

 

 

Q2 2023 vs Q2 2022

(€ thousands, except percentages)

H1 2023

 

% of

Revenues

 

H1 2022

 

% of

Revenues

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

Q2 2023

 

% of

Revenues

 

Q2 2022

 

% of

Revenues

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

903,059

 

100.0%

 

728,993

 

100.0%

 

23.9%

 

24.7%

 

21.5%

 

474,747

 

100.0%

 

351,414

 

100.0%

 

35.1%

 

37.4%

 

24.5%

Direct to Consumer (DTC)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zegna branded products

465,710

 

 

 

361,850

 

 

 

28.7%

 

30.3%

 

30.3%

 

236,114

 

 

 

177,941

 

 

 

32.7%

 

36.2%

 

36.2%

Thom Browne

82,924

 

 

 

66,174

 

 

 

25.3%

 

30.6%

 

30.6%

 

40,075

 

 

 

31,993

 

 

 

25.3%

 

33.7%

 

33.7%

Tom Ford Fashion

34,751

 

 

 

 

 

 

—%

 

n.m.

 

n.m.

 

34,751

 

 

 

 

 

 

—%

 

n.m.

 

n.m.

Total Direct to Customer (DTC)

583,385

 

64.6%

 

428,024

 

58.7%

 

36.3%

 

38.6%

 

30.4%

 

310,940

 

65.5%

 

209,934

 

59.7%

 

48.1%

 

52.8%

 

35.8%

Wholesale

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zegna branded products

75,609

 

 

 

63,402

 

 

 

19.3%

 

17.9%

 

17.9%

 

33,316

 

 

 

23,332

 

 

 

42.8%

 

43.0%

 

43.0%

Thom Browne

124,027

 

 

 

118,992

 

 

 

4.2%

 

4.2%

 

4.2%

 

54,324

 

 

 

55,236

 

 

 

(1.7%)

 

(1.5%)

 

(1.5%)

Tom Ford Fashion

29,264

 

 

 

 

 

 

n.m.

 

n.m.

 

n.m.

 

29,264

 

 

 

 

 

 

n.m.

 

n.m.

 

n.m.

Third Party Brands and Textile

88,549

 

 

 

116,309

 

 

 

(23.9%)

 

(24.9%)

 

4.2%

 

45,821

 

 

 

61,663

 

 

 

(25.7%)

 

(26.7%)

 

(3.8%)

Total Wholesale

317,449

 

35.2%

 

298,703

 

41.0%

 

6.3%

 

5.5%

 

7.6%

 

162,725

 

34.3%

 

140,231

 

39.9%

 

16.0%

 

15.6%

 

6.0%

Other

2,225

 

0.2%

 

2,266

 

0.3%

 

n.m.

 

n.m.

 

n.m.

 

1,082

 

0.2%

 

1,249

 

0.4%

 

n.m.

 

n.m.

 

n.m.

______________________________________

Zegna branded products include apparel, bags, shoes and small and large leather goods, as well as licensed goods and royalties.

The tables below show a reconciliation of revenue growth for the six months ended June 30, 2023 and for the three months ended June 30, 2023 to organic growth for the same periods by sales channel and at the Group level.

H1 2023 vs H1 2022

Revenues Growth

Foreign Exchange

Acquisitions and

disposals

Structural changes

in license

agreements where

Zegna operates

as a licensee

Organic Growth

Group

23.9 %

(0.8)%

8.8 %

(5.6)%

21.5 %

Direct to Consumer (DTC)
Zegna branded products

28.7 %

(1.6)%

— %

— %

30.3 %

Thom Browne

25.3 %

(5.3)%

— %

— %

30.6 %

Tom Ford Fashion n.m. n.m. n.m. n.m. n.m.
Total Direct to Customer (DTC)

36.3 %

(2.3)%

8.2 %

— %

30.4 %

Wholesale
Zegna branded products

19.3 %

1.4 %

— %

— %

17.9 %

Thom Browne

4.2 %

— %

— %

— %

4.2 %

Tom Ford Fashion n.m. n.m. n.m. n.m. n.m.
Third Party Brands and Textile

(23.9)%

1.0 %

(0.1)%

(29.0)%

4.2 %

Total Wholesale

6.3 %

0.8 %

9.7 %

(11.8)%

7.6 %

Other n.m. n.m. n.m. n.m. n.m.

 

Q2 2023 vs Q2 2022

 

Revenues Growth

 

Foreign Exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

 

Group

35.1%

 

(2.3%)

 

18.4%

 

(5.5%)

 

24.5%

Direct to Consumer (DTC)

 

 

 

 

 

 

 

 

 

Zegna branded products

32.7%

 

(3.5%)

 

—%

 

—%

 

36.2%

Thom Browne

25.3%

 

(8.4%)

 

—%

 

—%

 

33.7%

Tom Ford Fashion

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

Total Direct to Customer (DTC)

48.1%

 

(4.7%)

 

17.0%

 

—%

 

35.8%

Wholesale

 

 

 

 

 

 

 

 

 

Zegna branded products

42.8%

 

(0.2%)

 

—%

 

—%

 

43.0%

Thom Browne

(1.7%)

 

(0.2%)

 

—%

 

—%

 

(1.5%)

Tom Ford Fashion

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

Third Party Brands and Textile

(25.7%)

 

1.0%

 

(0.2%)

 

(22.7%)

 

(3.8%)

Total Wholesale

16.0%

 

0.4%

 

20.8%

 

(11.2%)

 

6.0%

Other

n.m.

 

n.m.

 

n.m.

 

n.m.

 

n.m.

______________________________________

Zegna branded products include apparel, bags, shoes and small and large leather goods, as well as licensed goods and royalties.

Group Revenues by Geographical Area (Preliminary and Unaudited)

 

 

 

 

 

H1 2023 vs H1 2022

 

 

 

 

 

Q2 2023 vs Q2 2022

(€ thousands, except percentages)

H1 2023

 

H1 2022

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

Q2 2023

 

Q2 2022

 

Reported

Revenues

 

Constant

Currency

 

Organic

Growth

 

 

 

 

 

 

 

 

 

 

Total revenues

903,059

 

728,993

 

23.9 %

 

24.7%

 

21.5%

 

474,747

 

351,414

 

35.1 %

 

37.4%

 

24.5%

EMEA (1)

322,680

 

260,627

 

23.8 %

 

24.2%

 

21.4%

 

172,572

 

126,171

 

36.8 %

 

37.9%

 

24.5%

of which Italy

151,464

 

125,996

 

20.2 %

 

20.0%

 

16.8%

 

77,030

 

61,905

 

24.4 %

 

24.1%

 

14.3%

of which UK

28,823

 

23,544

 

22.4 %

 

24.2%

 

21.5%

 

18,442

 

12,574

 

46.7 %

 

48.0%

 

24.3%

of which UAE

31,906

 

21,745

 

46.7 %

 

45.1%

 

44.0%

 

15,506

 

10,377

 

49.4 %

 

53.1%

 

50.8%

North America (2)

174,376

 

135,275

 

28.9 %

 

25.7%

 

16.3%

 

108,742

 

73,472

 

48.0 %

 

46.6%

 

16.2%

of which United States

156,747

 

124,291

 

26.1 %

 

22.9%

 

12.5%

 

98,712

 

67,358

 

46.5 %

 

45.3%

 

13.9%

Latin America (3)

15,736

 

12,525

 

25.6 %

 

16.5%

 

16.5%

 

8,963

 

6,860

 

30.7 %

 

23.9%

 

23.9%

APAC (4)

389,025

 

318,825

 

22.0 %

 

25.4%

 

24.3%

 

183,772

 

144,009

 

27.6 %

 

33.3%

 

28.7%

of which Greater China Region

306,835

 

247,193

 

24.1 %

 

27.7%

 

27.2%

 

142,309

 

105,213

 

35.3 %

 

42.0%

 

40.0%

of which Japan

39,597

 

30,240

 

30.9 %

 

37.8%

 

32.6%

 

20,942

 

16,101

 

30.1 %

 

36.8%

 

23.9%

Other (5)

1,242

 

1,741

 

(28.7) %

 

(28.9%)

 

(33.6%)

 

698

 

902

 

(22.6) %

 

(22.7%)

 

(31.9%)

________________________________________

(1)

EMEA includes Europe, the Middle East and Africa.

(2)

North America includes the United States of America and Canada.

(3)

Latin America includes Mexico, Brazil and other Central and South American countries.

(4)

APAC includes the Greater China Region, Japan, South Korea, Thailand, Malaysia, Vietnam, Indonesia, Philippines, Australia, New Zealand, India and other Southeast Asian countries.

(5)

Other revenues mainly include royalties.

The tables below show a reconciliation of revenue growth for the six months ended June 30, 2023 and for the three months ended June 30, 2023 to organic growth for the same periods by geographical area and at the Group level.

 

H1 2023 vs H1 2022

 

Revenues Growth

 

Foreign Exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

 

Group

23.9%

 

(0.8%)

 

8.8%

 

(5.6%)

 

21.5%

EMEA (1)

23.8%

 

(0.4%)

 

8.7%

 

(5.9%)

 

21.4%

of which Italy

20.2%

 

0.2%

 

6.3%

 

(3.1%)

 

16.8%

of which UK

22.4%

 

(1.8%)

 

20.7%

 

(18.0%)

 

21.5%

of which UAE

46.7%

 

1.6%

 

—%

 

1.1%

 

44.0%

North America (2)

28.9%

 

3.2%

 

23.3%

 

(13.9%)

 

16.3%

of which United States

26.1%

 

3.2%

 

23.3%

 

(12.9%)

 

12.5%

Latin America (3)

25.6%

 

9.1%

 

—%

 

—%

 

16.5%

APAC (4)

22.0%

 

(3.4%)

 

2.9%

 

(1.8%)

 

24.3%

of which Greater China Region

24.1%

 

(3.6%)

 

1.0%

 

(0.5%)

 

27.2%

of which Japan

30.9%

 

(6.9%)

 

9.1%

 

(3.9%)

 

32.6%

Other (5)

(28.7%)

 

0.2%

 

4.7%

 

—%

 

(33.6%)

 

Q2 2023 vs Q2 2022

 

Revenues Growth

 

Foreign Exchange

 

Acquisitions and

disposals

 

Structural changes

in license

agreements where

Zegna operates

as a licensee

 

Organic Growth

 

 

 

 

 

Group

35.1%

 

(2.3%)

 

18.4%

 

(5.5%)

 

24.5%

EMEA (1)

36.8%

 

(1.1%)

 

18.1%

 

(4.7%)

 

24.5%

of which Italy

24.4%

 

0.3%

 

12.7%

 

(2.9%)

 

14.3%

of which UK

46.7%

 

(1.3%)

 

38.6%

 

(14.9%)

 

24.3%

of which UAE

49.4%

 

(3.7%)

 

—%

 

2.3%

 

50.8%

North America (2)

48.0%

 

1.4%

 

43.7%

 

(13.3%)

 

16.2%

of which United States

46.5%

 

1.2%

 

44.0%

 

(12.6%)

 

13.9%

Latin America (3)

30.7%

 

6.8%

 

—%

 

—%

 

23.9%

APAC (4)

27.6%

 

(5.7%)

 

6.3%

 

(1.7%)

 

28.7%

of which Greater China Region

35.3%

 

(6.7%)

 

2.5%

 

(0.5%)

 

40.0%

of which Japan

30.1%

 

(6.7%)

 

16.7%

 

(3.8%)

 

23.9%

Other (5)

(22.6%)

 

0.1%

 

9.2%

 

—%

 

(31.9%)

________________________________________

(1)

EMEA includes Europe, the Middle East and Africa.

(2)

North America includes the United States of America and Canada.

(3)

Latin America includes Mexico, Brazil and other Central and South American countries.

(4)

APAC includes the Greater China Region, Japan, South Korea, Thailand, Malaysia, Vietnam, Indonesia, Philippines, Australia, New Zealand, India and other Southeast Asian countries.

(5)

Other revenues mainly include royalties.

***

Monobrand(1) Store Network at June 30, 2023

 

As of June 30, 2023

 

As of December 31, 2022

 

As of June 30, 2022

Stores

Zegna

 

Thom

Browne

 

Tom Ford

Fashion

 

Group

 

Zegna

 

Thom

Browne

 

Group

 

Zegna

 

Thom

Browne

 

Group

EMEA (2)

69

 

10

 

4

 

83

 

65

 

10

 

75

 

69

 

10

 

79

Americas (3)

55

 

7

 

11

 

73

 

53

 

7

 

60

 

51

 

5

 

56

APAC

122

 

49

 

36

 

207

 

121

 

46

 

167

 

122

 

38

 

160

Total Direct to Customer (DTC)

246

66

51

 

363

239

 

63

 

302

 

242

 

53

 

295

EMEA (2)

59

 

7

 

12

 

78

 

57

 

6

 

63

 

85

 

5

 

90

Americas (3)

63

 

3

 

51

 

117

 

64

 

4

 

68

 

68

 

3

 

71

APAC

35

 

33

 

7

 

75

 

35

 

32

 

67

 

33

 

30

 

63

Total Wholesale

157

43

70

 

270

156

 

42

 

198

 

186

 

38

 

224

Total

403

109

121

 

633

395

 

105

 

500

 

428

 

91

 

519

________________________________________

(1)

Monobrand store count includes our DOSs (which are divided into boutiques and outlets) and our Wholesale monobrand stores (including also monobrand franchisees).

(2)

Does not include any stores in Russia at June 30, 2023 or at December 31, 2022 (14 Wholesale stores in EMEA at June 30, 2022). Although some stores may still be operating at June 30, 2023, they have not been supplied by Zegna since February 2022 and have therefore been excluded from Zegna’s store count.

(3)

Americas include North America and Latin America.

***

Non-IFRS Financial Measures

Zegna’s management monitors and evaluates operating and financial performance using several non-IFRS financial measures including: adjusted earnings before interest and taxes (“Adjusted EBIT”), Adjusted EBIT Margin, revenues on a constant currency basis and revenues on an organic growth basis. Zegna’s management believes that these non-IFRS financial measures provide useful and relevant information regarding Zegna’s financial performance and financial condition, and improve the ability of management and investors to assess and compare the financial performance and financial position of Zegna with those of other companies. They also provide comparable measures that facilitate management’s ability to identify operational trends, as well as make decisions regarding future spending, resource allocations and other strategic and operational decisions. While similar measures are widely used in the industry in which Zegna operates, the financial measures that Zegna uses may not be comparable to other similarly named measures used by other companies nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.

Adjusted EBIT and Adjusted EBIT Margin

Adjusted EBIT is defined as profit or loss before income taxes plus financial income, financial expenses, foreign exchange losses/(gains) and the result from investments accounted for using the equity method, adjusted for income and costs which are significant in nature and that management considers not reflective of underlying operating activities.

Adjusted EBIT Margin is defined as Adjusted EBIT divided by revenues of the applicable period.

Zegna’s management uses Adjusted EBIT and Adjusted EBIT Margin for internal reporting to assess performance and as part of the forecasting, budgeting and decision-making processes as they provide additional transparency regarding Zegna’s underlying operating performance. Zegna’s management believes these non-IFRS financial measures are useful because they exclude items that management believes are not indicative of Zegna’s underlying operating performance and allow management to view operating trends, perform analytical comparisons and benchmark performance between periods and among segments. Zegna’s management also believes that Adjusted EBIT and Adjusted EBIT Margin are useful for investors and analysts to better understand how management assesses Zegna’s underlying operating performance on a consistent basis and to compare Zegna’s performance with that of other companies. Accordingly, management believes that Adjusted EBIT and Adjusted EBIT Margin provide useful information to third party stakeholders in understanding and evaluating Zegna’s operating results.

Constant Currency Revenues

In addition to presenting our revenues on a current currency basis, we also present certain revenue information on a constant currency basis (Constant Currency), which excludes the effects of foreign currency translation from our subsidiaries with functional currencies different from the Euro.

We calculate Constant Currency revenues by applying the current period average foreign currency exchange rates to translate prior period revenues of foreign subsidiaries expressed in local functional currencies different than the Euro.

We use revenues on a Constant Currency basis to analyze how our underlying revenues have changed between periods independent of the effects of foreign currency translation.

Revenues on a Constant Currency basis are not a substitute for revenues on a current currency basis or any IFRS-related measures, however we believe that revenues excluding the impact of foreign currency translation provide additional useful information to management and to investors in analyzing and evaluating our revenues and operating performance.

Organic Growth Revenues

In addition to presenting our revenues on a current currency basis, we also present certain revenue information on an organic growth basis (Organic Growth). Organic Growth is calculated as the change in revenues from period to period, excluding the effects of (a) foreign exchange, (b) acquisitions and disposals and (c) structural changes in license agreements where Zegna operates as a licensee.

In calculating Organic Growth, the following adjustments are made to revenues:

(a) foreign exchange: current period average foreign currency exchange rates are used to translate prior period revenues of foreign subsidiaries expressed in local functional currencies different than the Euro;

(b) acquisitions and disposals: revenues generated by entities, businesses or revenue-generating assets acquired or disposed of in the current year or prior year are excluded from both periods (acquisitions and disposals refer to share or asset deals or other changes in control of subsidiaries, associates or joint ventures);

(c) structural changes in license agreements where Zegna operates as a licensee: revenues generated from license agreements, where Zegna operates as a licensee, that experienced a structural change in the scope or perimeter in the current year or prior year are excluded from both periods, including changes to product categories, sales channels or geographies of the underlying license agreements.

We believe the presentation of Organic Growth is useful to better understand and analyze the underlying change in the Group’s revenues from period to period on a consistent perimeter and constant currency basis.

Revenues on an Organic Growth basis are not a substitute for revenues on a current currency basis or any IFRS-related measures, however we believe that revenues excluding the effects of (a) foreign exchange, (b) acquisitions and disposals and (c) structural changes in license agreements where Zegna operates as a licensee provide additional useful information to management and to investors in analyzing and evaluating our revenues and operating performance.

Investor Relations / Group Communications / Media

Francesca Di Pasquantonio / Clementina Tito

[email protected] / [email protected]

KEYWORDS: Italy Europe

INDUSTRY KEYWORDS: Retail Footwear Luxury Fashion

MEDIA:

Logo
Logo

Li-Cycle’s CEO and Co-founder Ajay Kochhar Provides Expert Insights on Electronic Waste & Battery Recycling Solutions Before the U.S. Senate Committee on Environment and Public Works

Li-Cycle’s CEO and Co-founder Ajay Kochhar Provides Expert Insights on Electronic Waste & Battery Recycling Solutions Before the U.S. Senate Committee on Environment and Public Works

TORONTO–(BUSINESS WIRE)–Li-Cycle Holdings Corp. (NYSE: LICY) (“Li-Cycle” or the “Company”), an industry leader in lithium-ion battery resource recovery and the leading lithium-ion battery recycler in North America, is pleased to announce that its CEO and co-founder, Ajay Kochhar, provided expert insights yesterday before the United States Senate Committee on Environment and Public Works for a hearing called, “Improving Capacity for Critical Mineral Recovery through Electronic Waste Recycling and Reuse.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727531947/en/

Li-Cycle’s CEO and co-founder Ajay Kochhar was invited to provide expert testimony on electronic waste and battery recycling solutions before the U.S. Senate Committee on Environment and Public Works on July 26, 2023. (Photo: Business Wire)

Li-Cycle’s CEO and co-founder Ajay Kochhar was invited to provide expert testimony on electronic waste and battery recycling solutions before the U.S. Senate Committee on Environment and Public Works on July 26, 2023. (Photo: Business Wire)

Mr. Kochhar was invited to provide expert insights at the hearing as key industry leaders and government officials discussed the important topic of electronic waste, or e-waste, and solutions to solve for challenges presented by the transition to clean energy in North America.

“Li-Cycle was proud to have the opportunity to share our perspective on e-waste and battery recycling at the Senate Committee hearing, which is indicative of the progress the U.S. has made to solve for the substantial quantities of e-waste that both end-of-life batteries and battery manufacturers will produce in the coming years,” said Ajay Kochhar, Li-Cycle’s CEO and co-founder. “I would like to extend our gratitude and thanks to Chairman Tom Carper, Ranking Member Shelley Moore Capito and the other members of the committee and commend them for holding a hearing to exchange views on lithium-ion battery recycling and how we can mitigate challenges associated with e-waste. Li-Cycle was founded to create localized, closed-loop supply chains for battery materials to support the sustainable transition to electrification. Increasing awareness of recycling solutions is key to help address e-waste to support this transition, in addition to establishing policies and incentives to support environmentally friendly recyclers.”

At the hearing Mr. Kochhar discussed the following topics:

  • How Li-Cycle’s safe, sustainable, and scalable Spoke & Hub Technologies™ return critical materials from lithium-ion batteries and battery manufacturing scrap back to the supply chain with up to an overall 95% recycling efficiency rate to support a circular economy.

  • Battery manufacturing scrap and how it is magnified by the clean energy transition, which further enhances the need for environmentally friendly recycling solutions.

  • The landscape for the broader recycling industry and how the demand for post-processing and resource recovery will outstrip capacity in North America for some time.

  • The significant benefits lithium-ion battery recycling can offer to support a domestic battery supply chain, including providing a valuable alternative source of materials, as well as a long-term, environmentally friendly solution to address e-waste.

  • Key policy initiatives that can be taken to support the emerging lithium-ion battery recycling industry, including exploring whether there should be minimum requirements for the amount of recycled content in every domestically produced battery, and clear and consistent regulations on the movement of batteries and black mass.

Watch the full webcast of the hearing here:

https://www.epw.senate.gov/public/index.cfm/2023/7/improving-capacity-for-critical-mineral-recovery-through-electronic-waste-recycling-and-reuse

Read Mr. Kochhar’s full written testimony at this LINK.

About Li-Cycle Holdings Corp.

Li-Cycle (NYSE: LICY) is a leading global lithium-ion battery resource recovery company and North America’s largest pure-play lithium-ion battery recycler, with a rapidly growing presence across Europe. The Company leverages its innovative, sustainable and patented Spoke & Hub Technologies™ to provide a safe, scalable, customer-centric solution to recycle all different types of lithium-ion batteries. Established in 2016, and with major customers and partners around the world, Li-Cycle recovers critical battery-grade materials to create a domestic closed-loop battery supply chain for a clean energy future. For more information, visit https://li-cycle.com/.

Forward-Looking Statements

Certain statements contained in this press release may be considered “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, Section 21 of the U.S. Securities Exchange Act of 1934, as amended, and applicable Canadian securities laws. Forward-looking statements may generally be identified by the use of words such as “believe”, “may”, “will”, “continue”, “anticipate”, “intend”, “expect”, “should”, “would”, “could”, “plan”, “potential”, “future”, “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. Forward-looking statements in this press release include but are not limited to statements about: the expectation that increasing awareness of recycling solutions is key to help address e-waste to support the sustainable transition to electrification, in addition to establishing policies and incentives to support environmentally friendly recyclers; the expectation that the demand for post-processing/resource recovery will outstrip capacity in North America for some time; and the expectation that lithium-ion battery recycling can provide a valuable alternative source of materials, as well as long-term, environmentally friendly solution to address e-waste. These statements are based on various assumptions, whether or not identified in this communication, including but not limited to assumptions regarding the timing, scope and cost of Li-Cycle’s projects; the processing capacity and production of Li-Cycle’s facilities; Li-Cycle’s ability to source feedstock and manage supply chain risk; Li-Cycle’s ability to increase recycling capacity and efficiency; Li-Cycle’s ability to obtain financing on acceptable terms; Li-Cycle’s ability to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners; general economic conditions; currency exchange and interest rates; compensation costs; and inflation. There can be no assurance that such estimates or assumptions will prove to be correct and, as a result, actual results or events may differ materially from expectations expressed in or implied by the forward-looking statements.

These forward-looking statements are provided for the purpose of assisting readers in understanding certain key elements of Li-Cycle’s current objectives, goals, targets, strategic priorities, expectations and plans, and in obtaining a better understanding of Li-Cycle’s business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and is not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Li-Cycle, and are not guarantees of future performance. Li-Cycle believes that these risks and uncertainties include, but are not limited to, the following: Li-Cycle’s inability to economically and efficiently source, recover and recycle lithium-ion batteries and lithium-ion battery manufacturing scrap, as well as third party black mass, and to meet the market demand for an environmentally sound, closed-loop solution for manufacturing waste and end-of-life lithium-ion batteries; Li-Cycle’s inability to successfully implement its global growth strategy, on a timely basis or at all; Li-Cycle’s inability to manage future global growth effectively; Li-Cycle’s inability to develop the Rochester Hub, and other future projects including its Spoke network expansion projects in a timely manner or on budget or that those projects will not meet expectations with respect to their productivity or the specifications of their end products; Li-Cycle’s failure to materially increase recycling capacity and efficiency; Li-Cycle may engage in strategic transactions, including acquisitions, that could disrupt its business, cause dilution to its shareholders, reduce its financial resources, result in incurrence of debt, or prove not to be successful; one or more of Li-Cycle’s current or future facilities becoming inoperative, capacity constrained or if its operations are disrupted; additional funds required to meet Li-Cycle’s capital requirements in the future not being available to Li-Cycle on acceptable terms or at all when it needs them; Li-Cycle expects to continue to incur significant expenses and may not achieve or sustain profitability; problems with the handling of lithium-ion battery cells that result in less usage of lithium-ion batteries or affect Li-Cycle’s operations; Li-Cycle’s inability to maintain and increase feedstock supply commitments as well as securing new customers and off-take agreements; a decline in the adoption rate of EVs, or a decline in the support by governments for “green” energy technologies; decreases in benchmark prices for the metals contained in Li-Cycle’s products; changes in the volume or composition of feedstock materials processed at Li-Cycle’s facilities; the development of an alternative chemical make-up of lithium-ion batteries or battery alternatives; Li-Cycle’s revenues for the Rochester Hub are derived significantly from a single customer; Li-Cycle’s insurance may not cover all liabilities and damages; Li-Cycle’s heavy reliance on the experience and expertise of its management; Li-Cycle’s reliance on third-party consultants for its regulatory compliance; Li-Cycle’s inability to complete its recycling processes as quickly as customers may require; Li-Cycle’s inability to compete successfully; increases in income tax rates, changes in income tax laws or disagreements with tax authorities; significant variance in Li-Cycle’s operating and financial results from period to period due to fluctuations in its operating costs and other factors; fluctuations in foreign currency exchange rates which could result in declines in reported sales and net earnings; unfavorable economic conditions, such as consequences of the global COVID-19 pandemic; natural disasters, unusually adverse weather, epidemic or pandemic outbreaks, cyber incidents, boycotts and geo-political events; failure to protect or enforce Li-Cycle’s intellectual property; Li-Cycle may be subject to intellectual property rights claims by third parties; Li-Cycle’s failure to effectively remediate the material weaknesses in its internal control over financial reporting that it has identified or if it fails to develop and maintain a proper and effective internal control over financial reporting. These and other risks and uncertainties related to Li-Cycle’s business are described in greater detail in the section entitled “Risk Factors” and “Key Factors Affecting Li-Cycle’s Performance” in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and the Ontario Securities Commission in Canada. Because of these risks, uncertainties and assumptions, readers should not place undue reliance on these forward-looking statements. Actual results could differ materially from those contained in any forward-looking statement.

Li-Cycle assumes no obligation to update or revise any forward-looking statements, except as required by applicable laws. These forward-looking statements should not be relied upon as representing Li-Cycle’s assessments as of any date subsequent to the date of this press release.

Investor Relations

Nahla A. Azmy

Sheldon D’souza

[email protected]

Media

Louie Diaz

[email protected]

KEYWORDS: United States North America Canada

INDUSTRY KEYWORDS: Environment Other Science Public Policy/Government Logistics/Supply Chain Management EV/Electric Vehicles Other Natural Resources Mining/Minerals Recycling Natural Resources Transport Other Technology Public Relations/Investor Relations Science Automotive Manufacturing Communications Manufacturing Other Energy Utilities Technology Alternative Energy Energy Batteries White House/Federal Government Automotive General Automotive

MEDIA:

Photo
Photo
Li-Cycle’s CEO and co-founder Ajay Kochhar was invited to provide expert testimony on electronic waste and battery recycling solutions before the U.S. Senate Committee on Environment and Public Works on July 26, 2023. (Photo: Business Wire)
Logo
Logo

Dole plc Schedules Second Quarter 2023 Earnings Release

Dole plc Schedules Second Quarter 2023 Earnings Release

DUBLIN–(BUSINESS WIRE)–
Dole plc (NYSE: DOLE) will announce its financial results for the second quarter of 2023 on Thursday, August 17, 2023, prior to the market opening. The company’s management will host a webcast and conference call on the same day at 08:00 a.m. Eastern Time.

A presentation to accompany the discussion will be posted on the company website along with a press release and other supplemental financial information.

The live webcast and a replay after the event can be accessed at www.doleplc.com/investor-relations

The conference call can be accessed live by dialling (646) 307-1963 in the US or +353 (1) 582 2023 in Ireland and +44 20 3481 4247 for UK and other international participants. The conference ID is 4317462.

About Dole plc:

A global leader in fresh produce, Dole plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place.

Category: Financial

Investor Contact:

James O’Regan, Head of Investor Relations, Dole plc

[email protected]

+353 1 887 2794

Media Contact:

Brian Bell, Ogilvy

[email protected]

+353 87 2436 130

KEYWORDS: California Europe Ireland United States North America

INDUSTRY KEYWORDS: Retail Food/Beverage Organic Food

MEDIA:

Logo
Logo

View, Inc. Completes Reverse Stock Split

Common Stock Begins Trading on Split-Adjusted Basis

MILPITAS, Calif., July 27, 2023 (GLOBE NEWSWIRE) — View, Inc. (Nasdaq: VIEW) (“View” or the “Company”) today announced that on July 26, 2023, View filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a 60-for-1 reverse stock split of the outstanding shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock,” and such reverse stock split, the “Reverse Stock Split”). The Reverse Stock Split became effective upon the filing of the Certificate of Amendment on July 26, 2023 (the “Effective Time”), and View’s Common Stock will begin trading on a split-adjusted basis at market open today, July 27, 2023.

The Reverse Stock Split is intended to bring the Company into compliance with the $1.00 minimum average closing share price requirement for continued listing on the Nasdaq Stock Market LLC (“Nasdaq”).

As a result of the Reverse Stock Split, every 60 shares of issued and outstanding Common Stock will be automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Instead, Continental Stock Transfer & Trust Company, the Company’s transfer agent (“Continental”), will aggregate all fractional shares and sell them as soon as practicable after the Effective Time at the then-prevailing prices on the open market, on behalf of those stockholders who would otherwise have been entitled to receive a fractional share as a result of the Reverse Stock Split. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from approximately 242,446,036 shares to approximately 4,040,767 shares, subject to adjustment for the treatment of fractional shares. The number of authorized shares of Common Stock under the Certificate of Incorporation will not be affected. A proportionate adjustment was also made to the maximum number of shares issuable under the Company’s 2021 Equity Incentive Plan.

Stockholders who hold their shares in book-entry form or in “street name” (through a broker, bank, or other holder of record) will not be required to take any action.

The Common Stock will begin trading on a split-adjusted basis on Nasdaq at the market open on July 27, 2023. The trading symbol for the Common Stock will remain “VIEW”. The new CUSIP number for the Common Stock following the Reverse Stock Split is 92671V 304.

About View

View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to outdoor conditions, eliminating the need for blinds and increasing access to natural light. Every View installation includes a cloud-connected smart building platform that can easily be extended to reimagine the occupant experience. View’s products are installed in offices, apartments, airports, hotels, and educational facilities. For more information, please visit: www.view.com.

Forward-Looking Statements

This press release and certain materials View files with the U.S. Securities and Exchange Commission (the “SEC”), as well as information included in oral statements or other written statements made or to be made by View, other than statements of historical fact, contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on current expectations, estimates, assumptions, projections and management’s beliefs, that are subject to change. There can be no assurance that these forward-looking statements will be achieved; these statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, many of which are beyond View’s control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. View’s business is subject to a number of risks which are described more fully in View’s Annual Report on Form 10-K for the year ended December 31, 2022, as amended, its Quarterly Reports on Form 10-Q and in its other filings with the SEC. View undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof.

Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to those described below. The effect of a reverse stock split on the per share trading price of View’s common stock cannot be predicted with any certainty, and the outcomes of reverse stock splits for other companies are varied, particularly given that investors may view a reverse stock split as a negative indicator. It is possible that the per share trading price of View’s common stock after the Reverse Stock Split will not increase in the same proportion as the reduction in the number of View’s outstanding shares of common stock following the Reverse Stock Split or at all, and the Reverse Stock Split may not result in a per share trading price that will attract investors who do not trade in lower priced stocks. View cannot assure you that following the Reverse Stock Split, its common stock will be more attractive to investors or that it will regain compliance with the $1.00 minimum average closing share price requirement for continued listing on Nasdaq. Following the Reverse Stock Split, the per share trading price of View’s common stock may decrease due to factors unrelated to the Reverse Stock Split, including View’s future performance. If the per share trading price of View’s common stock following the Reverse Stock Split declines, the percentage decline as an absolute number and as a percentage of View’s overall market capitalization may be greater than would occur in the absence of the Reverse Stock Split.

The Reverse Stock Split may decrease the liquidity of View’s common stock and result in higher transaction costs. The liquidity of View’s common stock may be negatively impacted by the Reverse Stock Split, given the reduced number of shares that are outstanding following the Reverse Stock Split, particularly if the per share trading price does not increase as a result of the Reverse Stock Split. In addition, the Reverse Stock Split will increase the number of View’s stockholders who own “odd lots” of fewer than 100 shares of common stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock.

Contacts:

View, Inc.
[email protected]
(408) 493-1358



California Water Service Group Announces Second Quarter 2023 Results

SAN JOSE, Calif., July 27, 2023 (GLOBE NEWSWIRE) — California Water Service Group (NYSE: CWT) (“Group”) today announced net income attributable to Group of $9.6 million and diluted earnings per share of $0.17 for the quarter ended June 30, 2023, as compared to net income attributable to Group of $19.5 million and diluted earnings per share of $0.36 for the quarter ended June 30, 2022.

Second quarter results primarily reflect the impact of the delayed proposed decision from the California Public Utilities Commission (“CPUC”) on California Water Service Company’s (“Cal Water”) 2021 general rate case (“GRC”). Group currently estimates the temporary impact of the delayed decision on second quarter 2023 operating revenue to be between approximately $19 million and $29 million, based on the current positions of the parties to the 2021 GRC filing and consumption-driven regulatory mechanisms.

On June 29, 2023, the CPUC extended the GRC completion date to December 31, 2023, and on July 13, 2023, the CPUC co-assigned a second Administrative Law Judge (“ALJ”) to the Cal Water GRC to facilitate the process. The final GRC decision, once approved, will be retroactive to January 1, 2023, and a cumulative adjustment will be recorded in the quarter in which final approval is received.

Operating revenue was $194.0 million for the quarter ended June 30, 2023, compared to $206.2 million for the same period in 2022. The $12.2 million, or 5.9%, revenue decrease was primarily due to a $7.1 million decrease in Water Revenue Adjustment Mechanism (WRAM) and Modified Cost Balancing Account (MCBA) revenue and a $6.7 million decrease in customer usage.

Water revenues billed in the second quarter of 2023 included a 4% interim rate increase effective May 5, 2023; however, second quarter 2023 operating revenue does not include any benefit of new revenue mechanisms (Monterey-Style Water Revenue Adjustment Mechanism and Drought Response Memorandum Account) or the full benefit of rate relief (tracked in the Interim Rates Memorandum Account) due to the delay in the 2021 GRC.

Total operating expenses for the second quarter of 2023 were $178.1 million, compared to $178.9 million in 2022, a decrease of $0.8 million or 0.5%, mostly due to decreases in other operations expenses and income taxes, which were partially offset by increases in administrative and general, depreciation and amortization, property and other taxes, and a change in water mix. Administrative and general expenses for the second quarter of 2023 increased $2.3 million, or 7.0%, to $35.0 million during the quarter, primarily due to a $1.9 million increase in labor costs. Other operations expenses for the second quarter of 2023 were $25.8 million, compared to $29.4 million in 2022, a decrease of $3.6 million, or 12.2%, mostly due to the deferral of $2.5 million in costs related to the revenue deferral and a $1.7 million decrease in bad debt expense. Property and other taxes increased $1.1 million, mostly due to an increase in property taxes. Depreciation and amortization increased $1.0 million, primarily due to utility plant placed in service in 2022. Income taxes decreased $1.2 million, mostly due to a reduction in net operating income.

Other income and expenses were $6.2 million in the second quarter of 2023, an increase of $3.3 million, or 111.9%, over the second quarter of 2022. The increase was primarily due to an increase in unrealized gains on certain non-qualified benefit plan investments of $5.2 million in the second quarter of 2023 compared to 2022, partially offset by a $2.2 million decrease related to a gain on company owned life insurance recorded in 2022.

Net interest expense in the second quarter of 2023 increased $1.7 million, or 15.4%, to $12.7 million as compared to the second quarter of 2022, mostly due to an increase in short-term borrowing rates and higher outstanding line of credit balances.

The effective consolidated income tax rate was approximately 14.9% and 11.5% for the quarters ended June 30, 2023, and 2022, respectively. The change in effective tax rates was primarily due to a reduction in the amortization of the Tax Cuts and Jobs Act excess deferred income tax benefits in 2023 as compared to 2022.

According to Chairman and Chief Executive Officer Martin A. Kropelnicki, Group achieved several positive outcomes in the second quarter, despite the regulatory delay.

“The delay in Cal Water’s 2021 GRC clearly had a temporary adverse impact on our results, and I am hopeful that having an additional Administrative Law Judge on the case will expedite the process. However, there is good news to report for the second quarter:

  • We received a decision on our Cost of Capital filing that is expected to increase our return on equity for California from 9.20% to 9.57% on July 31, 2023. The decision establishes a capital structure of 53.4% equity and 46.6% debt and reaffirms a Cost of Capital Adjustment Mechanism that allows for future changes based on Moody’s Utility Bond Index. We continued to invest diligently in our water system infrastructure to provide reliability and quality to customers. We’ve invested $177.2 million in capital year-to-date.
  • We received approval from the New Mexico Public Regulation Commission to acquire Monterey Water Company, a 380-connection system near our Rio Del Oro service area.
  • We ranked highest in the west among large water utilities in JD Powers’ Residential Customer Satisfaction Study.
  • We published our ESG Report, completed a greenhouse gas emissions inventory, and committed to setting absolute Scope 1 and 2 emissions reduction targets by Q3 2024.
  • We received a $4.3 million grant from the Department of Water Resources to connect struggling communities to our Salinas, California system.
  • We declared our 313th consecutive quarterly dividend.

The bottom line is that regulatory delays are eventually resolved, but our focus continues to be on executing our strategy,” Kropelnicki said.

Year-to-Date Results

For the six-month period ended June 30, 2023, net loss attributable to Group was $12.7 million or $0.23 loss per diluted common share, compared to net income attributable to Group of $20.6 million or $0.38 earnings per diluted common share for the six-month period ended June 30, 2022. Results for the six-month period ended June 30, 2023 reflect the impact of the delayed proposed decision from the CPUC on Cal Water’s pending 2021 GRC. We currently estimate the adverse impact of the delayed decision on the six-month period ended June 30, 2023 operating revenue to be between approximately $43.0 million and $63.0 million, which is based on the current positions of the parties to the 2021 GRC Filing and consumption driven regulatory mechanisms.

Operating revenue was $325.1 million for the six-month period ended June 30, 2023, compared to $379.2 million for the same period in 2022. The $54.1 million, or 14.3%, revenue decrease was primarily due to a $21.8 million increase in revenue deferral, a $15.2 million decrease in WRAM and MCBA revenue, and a $22.9 million decrease in customer usage, which was partially offset by rate increases in California of $5.0 million. The increase in revenue deferral was accompanied by a $17.8 million increase in cost deferral.

Operating expenses for the six-month period ended June 30, 2023 were $326.7 million, compared to $342.8 million in 2022, a decrease of $16.0 million or 4.7%. Other operations expenses for the six-month period ended June 30, 2023 were $42.4 million, compared to $55.3 million in 2022, a decrease of 23.2%, or $12.8 million. The decrease was primarily attributed to the deferral of $17.8 million in costs related to the revenue deferral. Water production costs decreased $6.6 million, or 5.0%, to $125.9 million in 2023 compared to $132.4 million in 2022. The decrease in water production costs was primarily attributable to a 9.7% decrease in customer usage. In addition, income taxes decreased $5.4 million due to a reduction in net operating income. These decreases were partially offset by increases in administrative and general expenses of $4.9 million, depreciation and amortization of $2.2 million, and property and other taxes of $1.5 million.

Other income and expenses were $13.4 million for the six-month period ended June 30, 2023, an increase of $7.8 million, or 138.3%, over the same period in 2022. The increase was primarily due to an increase in unrealized gains on certain non-qualified benefit plan investments of $9.8 million, partially offset by a $2.7 million decrease related to a gain on company owned life insurance recorded in 2022.

Net interest expense for the six-month period ended June 30, 2023 increased $2.8 million, or 12.6%, to $24.7 million as compared to the same period in 2022, primarily due to an increase in short-term borrowing rates and higher outstanding line of credit balances.

Liquidity and Financing

Group maintained $89.7 million of cash as of June 30, 2023, of which $34.1 million was classified as restricted, and had additional short-term borrowing capacity of $470.0 million, subject to meeting the borrowing conditions on the Group and Cal Water line of credit facilities. Group’s At-the-Market equity program increased cash by $112.7 million during the first six months of 2023. Group’s aged accounts receivable past due more than 60 days decreased from $17.9 million as of March 31, 2023 to $13.1 million as of June 30, 2023. In 2022, Cal Water began working with an outside service, PromisePay, to provide customers with flexible payment plans to help them pay delinquent bills. Cal Water collected $1.0 million from PromisePay and currently have PromisePay commitments of $2.6 million. Also, the State of California extended its arrearage program to help customers struggling to pay monthly water bills. The program covers delinquent customer balances sixty days past due or written-off during the period from June 16, 2021 to December 31, 2022. Cal Water will file an application with the State Water Resource Control Board to request funds at the end of Q3 2023.

On June 29, 2023, the CPUC approved our COC proceeding with an ROE of 9.05%, which is expected to increase to 9.57% on July 31, 2023 based on our June 30, 2023 WCCM filing. Additionally, our equity structure and WCCM remained unchanged. The next potential WCCM adjustment request would, if triggered, be filed in October 2023 for the WCCM period from October 1, 2022 to September 30, 2023.

Group invested $177.2 million in infrastructure improvements during the six-month period ended June 30, 2023 which was a 22.3% increase from the same period last year. Cal Water proposed to the CPUC spending $1.0 billion on new capital projects in 2022-2024. We evaluate new capital project expenditures in California in the context of the pending GRC filing and these may change as the case moves forward.

On July 26, 2023, the Board of Directors approved a quarterly cash dividend of $0.26 per share of common stock.

Other Information

All stockholders and interested investors are invited to attend the conference call on July 27, 2023 at 8:00 a.m. PT (11:00 a.m. ET) by dialing 1-800-715-9871 or 1-646-307-1963 and keying in ID# 1254947, or you may access the live audio webcast at https://edge.media-server.com/mmc/p/jietaah9. Please join at least 15 minutes in advance to ensure a timely connection to the call. A replay of the call will be available from 3:00 p.m. ET on Thursday, July 27, 2023 through Monday, September 25, 2023, at 1-800-770-2030 or 1-609-800-9909, ID# 1254947, or by accessing the webcast above. The call will be hosted by President and Chief Executive Officer Martin A. Kropelnicki, Vice President and Chief Financial Officer David B. Healey, and Vice President, Rates and Regulatory Affairs, Greg A. Milleman. Prior to the call, Cal Water will furnish a slide presentation on its website at 9:00 a.m. ET.

About California Water Service Group

California Water Service Group is the parent company of regulated utilities California Water Service, Hawaii Water Service, New Mexico Water Service, and Washington Water Service, as well as Texas Water Service, a utility holding company. Together, these companies provide regulated and non-regulated water and wastewater service to more than 2.1 million people in California, Hawaii, New Mexico, Washington, and Texas. California Water Service Group’s common stock trades on the New York Stock Exchange under the symbol “CWT.” Additional information is available online at www.calwatergroup.com.


This news release contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 (“PSLRA”). The forward-looking statements are intended to qualify under provisions of the federal securities laws for “safe harbor” treatment established by the PSLRA. Forward-looking statements in this news release are based on currently available information, expectations, estimates, assumptions and projections, and our management’s beliefs, assumptions, judgments and expectations about us, the water utility industry and general economic conditions. These statements are not statements of historical fact. When used in our documents, statements that are not historical in nature, including words like will, would, expects, intends, plans, believes, may, could, estimates, assumes, anticipates, projects, progress, predicts, hopes, targets, forecasts, should, seeks or variations of these words or similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this news release include, but are not limited to, statements describing future rates, expectations regarding the 2021 GRC filing and the regulatory process and the estimated impacts related thereto, and proposed capital expenditures. Forward-looking statements are not guarantees of future performance. They are based on numerous assumptions that we believe are reasonable, but they are open to a wide range of uncertainties and business risks. Consequently, actual results may vary materially from what is contained in a forward-looking statement. Factors that may cause actual results to be different than those expected or anticipated include, but are not limited to: the impact of the ongoing COVID-19 pandemic and related public health measures; our ability to invest or apply the proceeds from the issuance of common stock in an accretive manner; governmental and regulatory commissions’ decisions, including decisions on proper disposition of property; consequences of eminent domain actions relating to our water systems; changes in regulatory commissions’ policies and procedures


, such as the CPUC’s decision in 2020 to preclude companies from proposing fully decoupled WRAMs in their next GRC filing (which impacted our 2021 GRC filing related to our operations commencing in 2023)


; the outcome and timeliness of regulatory commissions’ actions concerning rate relief and other matters, including with respect to our 2021 GRC filing; increased risk of inverse condemnation losses as a result of climate change and drought; our ability to renew leases to operate water systems owned by others on beneficial terms; changes in California State Water Resources Control Board water quality standards; changes in environmental compliance and water quality requirements; electric power interruptions, especially as a result of Public Safety Power Shutoff (PSPS) programs; housing and customer growth; the impact of opposition to rate increases; our ability to recover costs; availability of water supplies; issues with the implementation, maintenance or security of our information technology systems; civil disturbances or terrorist threats or acts; the adequacy of our efforts to mitigate physical and cyber security risks and threats; the ability of our enterprise risk management processes to identify or address risks adequately; labor relations matters as we negotiate with the unions; changes in customer water use patterns and the effects of conservation, including as a result of drought conditions; our ability to complete, in a timely manner or at all, successfully integrate and achieve anticipated benefits from announced acquisitions; the impact of weather, climate change, natural disasters, and actual or threatened public health emergencies, including disease outbreaks, on our operations, water quality, water availability, water sales and operating results and the adequacy of our emergency preparedness; restrictive covenants in or changes to the credit ratings on our current or future debt that could increase our financing costs or affect our ability to borrow, make payments on debt or pay dividends; risks associated with expanding our business and operations geographically; the impact of stagnating or worsening business and economic conditions, including inflationary pressures, general economic slowdown or a recession, increasing interest rates, and changes in monetary policy; the impact of market conditions and volatility on unrealized gains or losses on our non-qualified benefit plan investments and our operating results; the impact of weather and timing of meter reads on our accrued unbilled revenue; and other risks and unforeseen events described in our SEC filings. When considering forward-looking statements, you should keep in mind the cautionary statements included in this paragraph, as well as the Annual 10-K, Quarterly 10-Q, and other reports filed from time-to-time with the Securities and Exchange Commission (SEC). We are not under any obligation, and we expressly disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

David Healey
(408) 367-8200 (analysts)

Shannon Dean
(408) 367-8243 (media)

CALIFORNIA WATER SERVICE GROUP        
CONDENSED CONSOLIDATED BALANCE SHEETS        
Unaudited        
             
(In thousands, except per share data) June 30   December 31  
       
2023
     
2022
   
ASSETS        
Utility plant:        
  Utility plant $ 4,715,310     $ 4,536,272    
  Less accumulated depreciation and amortization   (1,537,580 )     (1,477,402 )  
    Net utility plant   3,177,730       3,058,870    
Current assets:        
  Cash and cash equivalents   55,595       62,100    
  Restricted cash   34,069       22,925    
  Receivables:        
    Customers,net   62,978       55,079    
    Regulatory balancing accounts   61,333       66,826    
    Other, net   22,664       20,932    
  Unbilled revenue, net   39,171       33,140    
  Materials and supplies   13,862       12,564    
  Taxes, prepaid expenses, and other assets   22,184       21,969    
    Total current assets   311,856       295,535    
Other assets:        
  Regulatory assets   276,592       283,620    
  Goodwill   36,814       36,814    
  Other assets   187,209       175,913    
    Total other assets   500,615       496,347    
TOTAL ASSETS $ 3,990,201     $ 3,850,752    
             
CAPITALIZATION AND LIABILITIES        
Capitalization:        
  Common stock, $.01 par value; 136,000 shares authorized, 57,702 and 55,598 outstanding in 2023 and 2022, respectively $ 577     $ 556    
  Additional paid-in capital   873,923       760,336    
  Retained earnings   515,016       556,698    
  Noncontrolling interests   4,451       4,804    
    Total equity   1,393,967       1,322,394    
  Long-term debt, net   1,052,070       1,052,487    
    Total capitalization   2,446,037       2,374,881    
Current liabilities:        
  Current maturities of long-term debt, net   1,825       3,310    
  Short-term borrowings   130,000       70,000    
  Accounts payable   138,272       140,986    
  Regulatory balancing accounts   29,277       12,240    
  Accrued interest   7,164       6,490    
  Accrued expenses and other liabilities   56,119       61,624    
    Total current liabilities   362,657       294,650    
Deferred income taxes   327,856       330,251    
Pension   80,008       78,443    
Regulatory liabilities and other   283,496       287,294    
Advances for construction   200,213       199,832    
Contributions in aid of construction   289,934       285,401    
Commitments and contingencies        
TOTAL CAPITALIZATION AND LIABILITIES $ 3,990,201     $ 3,850,752    

CALIFORNIA WATER SERVICE GROUP      
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
Unaudited      
(In thousands, except per share data)      
           
For the Three Months ended:      
      June 30   June 30
       
2023
     
2022
 
           
Operating revenue $ 194,044     $ 206,194  
Operating expenses:      
  Operations:      
    Water production costs   70,867       70,907  
    Administrative and general   34,975       32,686  
    Other operations   25,823       29,417  
  Maintenance   7,155       7,615  
  Depreciation and amortization   29,824       28,773  
  Income tax expense   329       1,454  
  Property and other taxes   9,122       8,053  
  Total operating expenses   178,095       178,905  
    Net operating income   15,949       27,289  
Other income and expenses:      
  Non-regulated revenue   4,485       7,002  
  Non-regulated expenses   (2,957 )     (8,541 )
  Other components of net periodic benefit credit   4,756       3,765  
  Allowance for equity funds used during construction   1,355       1,042  
  Income tax expense on other income and expenses   (1,445 )     (345 )
    Net other income   6,194       2,923  
Interest expense:      
  Interest expense   13,491       11,586  
  Allowance for borrowed funds used during construction   (795 )     (589 )
    Net interest expense   12,696       10,997  
Net income   9,447       19,215  
Net loss attributable to noncontrolling interests   (109 )     (269 )
Net income attributable to California Water Service Group $ 9,556     $ 19,484  
Earnings per share of common stock      
  Basic $ 0.17     $ 0.36  
  Diluted $ 0.17     $ 0.36  
Weighted average shares outstanding      
  Basic   56,692       54,007  
  Diluted   56,730       54,042  
Dividends per share of common stock $ 0.26     $ 0.25  
           
           
           
CALIFORNIA WATER SERVICE GROUP      
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
Unaudited      
(In thousands, except per share data)      
           
For the Six Months ended:      
      June 30   June 30
       
2023
     
2022
 
           
Operating revenue $ 325,144     $ 379,187  
Operating expenses:      
  Operations:      
    Water production costs   125,875       132,445  
    Administrative and general   70,961       66,097  
    Other operations   42,427       55,269  
  Maintenance   15,133       14,956  
  Depreciation and amortization   59,739       57,543  
  Income tax (benefit) expense   (5,315 )     37  
  Property and other taxes   17,899       16,413  
  Total operating expenses   326,719       342,760  
    Net operating (loss) income   (1,575 )     36,427  
Other income and expenses:      
  Non-regulated revenue   9,108       12,199  
  Non-regulated expenses   (5,232 )     (15,527 )
  Other components of net periodic benefit credit   9,977       7,779  
  Allowance for equity funds used during construction   2,759       2,017  
  Income tax expense on other income and expenses   (3,239 )     (857 )
    Net other income   13,373       5,611  
Interest expense:      
  Interest expense   26,309       23,081  
  Allowance for borrowed funds used during construction   (1,624 )     (1,152 )
    Net interest expense   24,685       21,929  
Net (loss) income   (12,887 )     20,109  
Net loss attributable to noncontrolling interests   (232 )     (461 )
Net (loss) income attributable to California Water Service Group $ (12,655 )   $ 20,570  
(Loss) earnings per share of common stock:      
  Basic $ (0.23 )   $ 0.38  
  Diluted $ (0.23 )   $ 0.38  
Weighted average shares outstanding      
  Basic   56,182       53,870  
  Diluted   56,182       53,918  
Dividends per share of common stock $ 0.52     $ 0.50  
           



Li Auto Inc. to Report Second Quarter 2023 Financial Results on August 8, 2023

BEIJING, China, July 27, 2023 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it will report its unaudited financial results for the second quarter of 2023 before the U.S. market opens on Tuesday, August 8, 2023.

The Company’s management will hold an earnings conference call on Tuesday, August 8, 2023, at 8:00 A.M. U.S. Eastern Time or 8:00 P.M. Beijing/Hong Kong Time on the same day.

For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time. Upon registration, participants will receive the conference call access information, including dial-in numbers, passcode, and a unique access PIN. To join the conference, please dial the number provided, enter the passcode followed by your PIN, and you will join the conference instantly.

Participant Online Registration: https://s1.c-conf.com/diamondpass/10032372-jb217p.html

A replay of the conference call will be accessible through August 15, 2023, by dialing the following numbers:

United States: +1-855-883-1031
Mainland, China: +86-400-1209-216
Hong Kong, China: +852-800-930-639
International: +61-7-3107-6325
Replay PIN: 10032372
   

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.lixiang.com.

About Li Auto Inc.

Li Auto Inc. is a leader in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Create a Mobile Home, Create Happiness (创造移动的家, 创造幸福的家). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer to successfully commercialize extended-range electric vehicles in China. The Company started volume production in November 2019. Its current model lineup includes Li L9, a six-seat flagship family SUV, Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The Company leverages technology to create value for its users. It concentrates its in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions while expanding its product line by developing new BEVs and EREVs to target a broader user base.

For more information, please visit: http://ir.lixiang.com.

For investor and media inquiries, please contact:

Li Auto Inc.
Investor Relations
Email: [email protected]

The Piacente Group, Inc.
Yang Song
Tel: +86-10-6508-0677
Email: [email protected]

Brandi Piacente
Tel: +1-212-481-2050
Email: [email protected]



Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023

IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN)(“Sientra” or the “Company”), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.  

The dial-in numbers are (844) 735-3763 for domestic callers and (412) 317-5711 for international callers.

A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at www.sientra.com. The webcast will be archived on the website following the completion of the call.

About Sientra

Headquartered in Irvine, California, Sientra is a medical aesthetics company focused on empowering people to change their lives through increased self-confidence and self-respect. Backed by unrivaled clinical and safety data, Sientra’s platform of products includes a comprehensive portfolio of round and shaped breast implants, the first fifth-generation breast implants approved by the FDA for sale in the United States, the ground-breaking AlloX2 breast tissue expander with patented dual-port and integral drain technology, the next-generation AlloX2Pro™, the first and only FDA-cleared MRI-compatible tissue expander, the Viality™ with AuraClens™ enhanced viability fat transfer system, the SimpliDerm Human Acellular Dermal Matrix, and BIOCORNEUM the #1 performing, preferred and recommended scar gel of plastic surgeons (*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

To learn more about Sientra, visit our website and follow Sientra on LinkedIn, Instagram, and Facebook.

(*) Data on file

Investor Relations Contact

Aman R. Patel, CFA
[email protected]

 



Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

  • No Change to Full-Year Forecasts or Management Guidance
  • Revenue Growth of +8.9% at Actual Exchange Rate (AER); +3.7% Growth at Constant Exchange Rate (CER), Driven by Growth & Launch Products (+16.2% at CER)
  • Reported Operating Profit Growth of +12.0% at AER; Core Operating Profit Decline of -2.0% at CER Reflecting Generic Impact, Lower Demand for Coronavirus Vaccines and Increased Investment in R&D and Data & Technology
  • Core Operating Profit Margin of 30.8%
  • Anticipated Pipeline Advances with 8 Key Regulatory Decisions Expected by End of FY2023, Furthering Commitment to Delivering Life-transforming Medicines to Patients

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023).

Takeda chief financial officer, Costa Saroukos, commented:

“Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing to a core operating profit margin of 30.8%. While we still anticipate headwinds affecting our business this fiscal year, largely due to generic competition, we remain confident of a return to growth in the near-term.

“Our growing product portfolio and innovative pipeline demonstrate the value of our strategic investments to strengthen our long-term competitiveness and enable our vision of discovering and delivering life-transforming treatments.”

FINANCIAL HIGHLIGHTS

Results for FY2023 Q1 Ended June 30, 2023

(Billion yen,

except

percentages and

per share amounts)

REPORTED

CORE(c)

(Non-IFRS)(a)

FY2023 Q1

vs. PRIOR YEAR

(AER % change(d))

FY2023 Q1

vs. PRIOR YEAR

(AER % change(d))

vs. PRIOR YEAR

(CER % change(d))

Revenue

1,058.6

+8.9%

1,058.6

+8.9%

+3.7%

Operating Profit

168.6

+12.0%

326.3

+2.3%

-2.0%

Margin

15.9%

+0.4pp

30.8%

-2.0pp

 

 

Net Profit

89.4

-14.9%

233.4

+4.1%

+0.9%

EPS (yen)

58

-15.4%

150

+3.5%

+0.3%

Operating Cash Flow

92.4

+9.7%

 

 

Free Cash Flow

(Non-IFRS)(a)(b)

-207.5

N/A

 

 

(a) Further information regarding certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/financial-results/.

(b) We define Free Cash Flow as cash flows from operating activities, subtracting acquisition of property, plant and equipment (“PP&E”), intangible assets and investments as well as removing any other cash that is not available to Takeda’s immediate or general business use, and adding proceeds from sales of PP&E, as well as from sales of investments and businesses, net of cash and cash equivalents divested.

(c) Core results adjust our reported results calculated and presented pursuant to IFRS to exclude the effect of items unrelated to Takeda’s core operations, such as, to the extent applicable for each line item, non-recurring items, purchase accounting effects and transaction related costs, as well as amortization and impairment of intangible assets and other operating income and expenses.

(d) Actual Exchange Rate is presented in “AER” (which is presented in accordance with IFRS). Constant Exchange Rate (CER) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

FY2023 Outlook (unchanged from May 2023)

(Billion yen)

FY2023

FORECAST

FY2023

MANAGEMENT GUIDANCE

Core Change at CER

(Non-IFRS)

Revenue

3,840.0

 

Core Revenue

3,840.0

Low-single-digit % decline

Reported Operating Profit

349.0

 

Core Operating Profit

1,015.0

Low-10s % decline

Reported Net Profit

142.0

 

Reported EPS (Yen)

91

 

Core EPS (Yen)

434

Low-20s % decline

Free Cash Flow*

400.0 – 500.0

 

Annual Dividend per Share (Yen)

188

 

*Free Cash Flow guidance reflects expenditures related to the acquisition of TAK-279 from Nimbus (USD 1.0 billion) and in-licensing of fruquintinib from HUTCHMED (USD 400 million). In FY2022, Takeda paid USD 3.0 billion out of USD 4.0 billion upfront payment related to the acquisition of TAK-279. For the remaining USD 1.0 billion payment, Takeda paid USD 0.9 billion in April 2023, with USD 0.1 billion to be paid in August 2023.

Additional Information About Takeda’s Q1 Earnings Results

For more details on Takeda’s FY2023 Q1 results and other financial information, including key assumptions in FY2023 forecast and management guidance, please visit: https://www.takeda.com/investors/financial-results/.

For more information on Takeda’s commercial progress across the five key business areas and pipeline updates, please visit: https://takeda.info/qr2023_q1_qfr_en

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Financial information and Certain Non-IFRS Financial Measures

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance and core results, including when controlling for the effect of fluctuations in exchange rates. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures, which are in the financial appendix at the end of Takeda’s FY2023 Q1 investor presentation (available at takeda.com/investors/financial-results).

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Please refer to slide 14 of Takeda’s FY2023 Q1 investor presentation (available at takeda.com/investors/financial-results) for the definition of Growth & Launch Products.

Investor Relations

Christopher O’Reilly

[email protected]

+81 (0) 3-3278-2543

Media Relations

Brendan Jennings

[email protected]

+81 (0) 3-3278-2111

KEYWORDS: Massachusetts United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Science Neurology Biotechnology Research Pharmaceutical Oncology Health Infectious Diseases

MEDIA:

Logo
Logo

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

  • $269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales
  • VYVGART® Hytrulo now available in the U.S. with first vials shipped in July
  • Global VYVGART expansion continued with commercial launch in Italy and distribution agreement with Handok in South Korea
  • Topline results from ADVANCE-SC and ADDRESS expected in fourth quarter of 2023
  • Management to host conference call today at 2:30 pm CET (8:30 am ET)


July 27
, 202
3

Amsterdam
, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2023 financial results and provided a second quarter business update.

“We are thrilled to see the momentum continue across all aspects of our business, with a catalyst-rich first half of the year. For another quarter we saw consistent revenue growth with VYVGART, delivering on our promise to bring transformative change to the treatment of gMG and reaching more patients through global approvals and the launch of our SC offering. Now with the positive ADHERE data, we have strengthened our conviction in the potential of VYVGART for CIDP patients but also more broadly across IgG-mediated autoimmune diseases, motivating us to explore the full extent of the opportunity. Our ambition level is high and we are positioning argenx for long-term growth with VYVGART, empasiprubart, and our pipeline of immunology solutions. It is time to raise the bar for patients on what a treatment can offer and we are more inspired than ever in our pursuit to do so,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

SECOND
QUARTER 202
3
AND RECENT BUSINESS UPDATE

VYVGART
Expansion

VYVGART is a first-in-class antibody fragment targeting the neonatal Fc receptor (FcRn) and is now approved globally in six countries or regions (U.S., Japan, EU, UK, Israel, China) for generalized myasthenia gravis (gMG). VYVGART Hytrulo was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2023, and is the first subcutaneous (SC) injectable for gMG. argenx is planning for multi-dimensional expansion to reach more patients with VYVGART through additional global regulatory approvals.

  • Generated global net VYVGART revenues of $269 million in second quarter of 2023
  • Launched VYVGART Hytrulo in U.S. and shipped first vials in July
  • Launched VYGART in Italy in July following successful completion of reimbursement negotiations
  • VYVGART approval decision in Canada expected in third quarter of 2023
  • Approval decisions of SC efgartigimod expected in Europe in fourth quarter of 2023, Japan by first quarter of 2024, and China by end of 2024
  • Marketing authorization application (MAA) filed in Japan for VYVGART for primary immune thrombocytopenia (ITP); approval decision expected in first half of 2024
  • Entered into VYVGART commercial and distribution agreement with Handok in South Korea

Efgartigimod Research and Development

argenx is solidifying its leadership in immunology innovation by expanding the scope of IgG-mediated autoimmune diseases in development and further demonstrating the potential of FcRn blockade in ongoing clinical trials. By the end of 2023, efgartigimod is expected to be approved, in regulatory review or in development in 13 severe autoimmune diseases.

  • Announced positive topline results from ADHERE of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP)
    • Primary endpoint met (p=0.000039); VYVGART Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo
    • 67% of patients in open-label Stage A demonstrated evidence of clinical improvement (ECI), indicating IgG autoantibodies play significant role in underlying biology of CIDP
    • Safety and tolerability profile consistent with confirmed safety profile of VYVGART
    • 91% (226/249) of eligible patients continued to ADHERE+ open-label extension study
  • Topline data from ADDRESS (pemphigus) and ADVANCE-SC (primary immune thrombocytopenia) studies expected in fourth quarter of 2023
  • GO/NO GO decisions expected from BALLAD (bullous pemphigoid) in first quarter of 2024 and ALKIVIA (myositis) in second half of 2024
  • Topline data from ALPHA (post-COVID postural orthostatic tachycardia syndrome (PC-POTS)) expected in first quarter of 2024 and RHO (Sjogren’s syndrome) in second half of 2024
  • Studies ongoing in membranous nephropathy (MN) and lupus nephritis (LN) through Zai Lab collaboration
  • Registrational study in thyroid eye disease (TED) and proof-of-concept studies in ANCA-associated vasculitis (ANCA) and antibody mediated rejection (AMR) in kidney transplant to start in fourth quarter of 2023

Pipeline
Progress

argenx is advancing a robust portfolio of innovative clinical programs, including empasiprubart (C2 inhibitor) and ARGX-119 (muscle-specific kinase (MuSK) agonist). Both programs have the potential to be first-in-class opportunities for multiple severe indications.

  • Initiated second dose cohort in Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy (MMN)
    • Independent Data Monitoring Committee recommended study continuation based on favorable safety profile observed in first dose cohort
    • Early efficacy signals support proof-of-concept in MMN
    • Second cohort to evaluate next dose of empasiprubart based on efficacy signals observed in first cohort
    • Topline results from both first and second cohorts expected in 2024
  • Phase 2 studies of empasiprubart in delayed graft function (DGF) on track to start by end of year and dermatomyositis in first quarter of 2024
  • Phase 1 study of ARGX-119 ongoing in healthy volunteers; subsequent Phase 1b trial to assess early signal detection in patients with congenital myasthenic syndrome and amyotrophic lateral sclerosis (ALS)

Immunology Innovation Program

argenx continues to invest in its discovery engine, the Immunology Innovation Program, to foster a robust innovation ecosystem and drive early-stage pipeline growth. argenx expects to nominate one new pipeline candidate in 2023.

SECOND
QUARTER
202
3
FINANCIAL RESULTS

    Three Months Ended

June 30,
  Six Months Ended

June 30,
(in thousands of $ except for shares and EPS)   2023   2022   2023   2022
Product net sales   $ 269,313   $ 74,833   $ 487,335   $ 95,996
Collaboration revenue     1,237     361     2,355     2,610
Other operating income     10,485     9,989     21,225     18,057
Total operating income     281,035     85,183     510,915     116,663
                         
Cost of sales     (24,024)     (5,010)     (42,359)     (6,382)
Research and development expenses     (195,509)     (126,919)     (361,364)     (278,887)
Selling, general and administrative expenses     (161,977)     (127,798)     (311,149)     (228,664)
Loss from investment in joint venture     (1,619)         (1,880)    
Total operating expenses     (383,129)     (259,727)     (716,752)     (513,933)
                         
Operating loss   $ (102,094)   $ (174,544)   $ (205,837)   $ (397,270)
                         
Financial income     20,441     4,912     37,029     5,733
Financial expense     (207)     (1,178)     (395)     (2,131)
Exchange gains/(losses)     (2,001)     (46,169)     9,164     (53,382)
                         
Loss for the period before taxes   $ (83,861)   $ (216,979)   $ (160,039)   $ (447,050)
Income tax (expense)/benefit   $ (10,507)   $ 8,229   $ 36,800   $ 11,114
Loss for the period   $ (94,368)   $ (208,750)   $ (123,239)   $ (435,936)
Loss for the
period
attributable to:
                       
Owners of the parent   $ (94,368)   $ (208,750)   $ (123,239)   $ (435,936)
Weighted average number of shares outstanding     55,828,239     54,802,339     55,690,873     53,449,915
Basis and diluted loss per share (in $)     (1.69)     (3.81)     (2.21)     (8.16)
Net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2021 and 2022                 (195,580)     260,665
Cash and cash equivalents and current financial assets at the end of the period                 1,996,968     2,597,393

DETAILS OF THE FINANCIAL RESULTS

Total operating income for the second quarter and year-to-date in 2023 was $281.0 million and $510.9 million, respectively, compared to $85.2 million and $116.7 million for the same periods in 2022, and mainly consists of:

  • Product net sales of VYVGART for the three months ended and six months ended June 30, 2023, were $269.3 million and $487.3 million, compared to $74.8 million and $96.0 million for the same periods in 2022.
  • Other operating income for the second quarter and year-to-date in 2023 was $10.5 million and $21.2 million, respectively, compared to $10.0 million, and $18.1 million for the same periods in 2022. The other operating income for the three and six months ended June 30, 2023 primarily relates to research and development tax incentives and payroll tax rebates.

Total operating expenses for the second quarter and year-to-date in 2023 were $383.1 million and $716.8 million, respectively, compared to $259.7 million and $513.9 million for the same periods in 2022, and mainly consists of:

  • Cost of sales for the second quarter and year-to-date in 2023 was $24.0 million and $42.4 million, respectively, compared to $5.0 million and $6.4 million for the same periods in 2022. The cost of sales was recognized with respect to the sale of VYVGART.
  • Research and development
    expenses increased by $68.6 million and $82.5 million for the three months and six months ended June 30, 2023, to $195.5 million and $361.4 million, respectively, compared to $126.9 million and $278.9 million for the same periods in 2022. The research and development expenses mainly relate to external research and development expenses and personnel expenses incurred in the clinical development of efgartigimod in various indications and the expansion of other clinical and preclinical pipeline candidates.
  • Selling, general and administrative
    expenses for the second quarter and year-to-date in 2023 were $162.0 million and $311.1 million, respectively, compared to $127.8 million and $228.7 million for the same periods in 2022. The selling, general and administrative expenses mainly relate to professional and marketing fees linked to commercialization of VYVGART in the U.S., EU and Japan, and personnel expenses.

Financial income for the second quarter and year-to-date in 2023 was $20.4 million and $37.0 million, respectively, compared to $4.9 million and $5.7 million for the same periods in 2022. The increase in financial income is mainly due to an increase in interest income on current financial assets and cash and cash equivalents attributable to higher interest rates.

Exchange gains/losses for the second quarter and year-to-date in 2023 were $2.0 million of exchange losses and $9.2 million of exchange gains, respectively, compared to $46.2 million and $53.4 million of exchange losses for the same periods in 2022. Exchange gains/losses are mainly attributable to unrealized exchange rate gains or losses on the cash, cash equivalents and current financial assets position in Euro.

Income tax for the second quarter and year-to-date in 2023 was $10.5 million of tax expense and $36.8 million of tax benefit, respectively, compared to $8.2 million and $11.1 million of tax benefit for the same periods in 2022.

Net loss for the three and six month periods ended June 30, 2023, was $94.4 million and $123.2 million, respectively, compared to $208.8 million and $435.9 million over the prior year periods. On a per weighted average share basis, the net loss was $2.21 and $8.16 for the six months ended June 30, 2023 and 2022, respectively.

Cash, cash equivalents and current financial assets totalled $2.0 billion as of June 30, 2023, compared to $2.2 billion as of December 31, 2022. Cash and cash equivalents and current financial assets decreased primarily as a result of net cash flows used in operating activities. The cash position as of June 30, 2023, excludes the $1.3 billion in estimated gross proceeds from the global equity offering, which closed on July 24, 2023.

With the closing of this transaction, argenx will review its cash burn expectations and provide an update accordingly.

UPCOMING
FINANCIAL CALENDAR

  • October 31, 2023: Q3 2023 financial results and business update
  • February 29, 2024: FY 2023 financial results and business update

CONFERENCE CALL DETAILS

The second quarter 2023 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website.

Dial-in numbers:

Please dial in 15 minutes prior to the live call.

Belgium                32 800 50 201
France                        33 800 943355
Netherlands                31 20 795 1090
United Kingdom        44 800 358 0970
United States                 1 888 415 4250
Japan                        81 3 4578 9081
Switzerland                41 43 210 11 32

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Erin Murphy
[email protected]

Investors
:

Alexandra Roy (US)
[email protected]

Lynn Elton (EU)
[email protected]

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “hope,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or “should” and include statements argenx makes regarding its plans for its global commercial expansion of VYVGART to reach more patients; continued investment in its Immunology Innovation Program to foster a robust innovation ecosystem and drive early-stage pipeline growth; the therapeutic potential of its product candidates; the intended results of its strategy and its collaboration partners’, including ongoing studies through its collaboration with
Zai
Lab; advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the (1) expected
topline
data from registrational ADDRESS and ADVANCE-SC studies in 2023, (2) expected GO/NO GO decisions from its BALLAD and ALKIVIA trials in 2024, (3) expected
topline
data from its ALPHA and RHO trials in 2024, (4) timeline of registrational and proof-of-concept studies in ANCA-associated vasculitis and antibody mediated rejection in kidney transplant, (5) potential of
empasiprubart
and ARGX-119 to be first-in-class opportunities for multiple serious indications and timeline of studies and results thereof and (6) planned nomination of a new product development candidate in 2023; the timing and outcome of regulatory filings and regulatory approvals, including the anticipated regulatory approvals of VYVGART in Canada and Japan and approvals of SC efgartigimod in Europe, Japan and China, and the number of autoimmune diseases for which efgartigimod is expected to be approved, in regulatory review or in development by end of 2023; and 2023 business and financial outlook and related plans, including the anticipated release of updated cash burn expectations and the timeline of future releases of financial results and business updates. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance.
argenx’s
actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including inflation and deflation and the corresponding fluctuations in interest rate; regional instability and conflicts, such as the conflict between Russia and Ukraine,
argenx’s
expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements;
argenx’s
reliance on
collaborations
with third parties; estimating the commercial potential of
argenx’s
product candidates;
argenx’s
ability to obtain and maintain protection of intellectual property for its technologies and drugs;
argenx’s
limited operating history; and
argenx’s
ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in
argenx’s
U.S. Securities and Exchange Commission (SEC) filings and reports, including in
argenx’s
most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the
SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.